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ABSTRACT 
 
Introduction  
 
Studies have shown an increased risk of mortality amongst adults with invasive 
pneumococcal disease (IPD) with certain serotypes but there are no data from 
South Africa. We aimed to determine the association between serotypes and in-
hospital mortality among adults aged 15 years and older with IPD in South Africa. 
 
Methods 
 
IPD cases were identified through the GERMS-SA national laboratory-based 
surveillance programme. Patient data from 25 enhanced surveillance sites from 
2003-2008 (pre-pneumococcal conjugate vaccine introduction) with available data 
on serotype and in-hospital outcome were used. We assessed the association 
between the 20 most common serotypes and mortality among patients ≥15 years 
of age using univariate and multivariable logistic regression models. 
 
Results 
 
From January 2003 through December 2008, there were 3953 cases of IPD 
amongst adults older than 15 years of age meeting the study inclusion criteria. 
Amongst the 20 commonest serotypes, the incidence of serotypes 4, 19A, 23F 
and 18C increased significantly, and serotypes 1, 25 and 5 decreased significantly 
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from 2003 to 2008. Serotype 1 was the commonest serotype overall (16%, 
651/3953), followed by serotype 19A (11%, 443/3953) and serotype 4 (7%, 
289/3953). The case-fatality ratio (CFR) was 55% (641/1166) for meningitis and 
23% (576/2484) for bacteremia (p<0.001). Serotype 19F had the highest CFR of 
48% (100/207), followed by 39% (99/252) for serotype 23F and 38% (246/651) for 
serotype 1. On multivariable analysis, factors independently associated with 
mortality were disease caused by serotypes 1 (OR 1.93, 95% CI 1.05–3.53) and 
19F (OR 2.89, 95% CI 1.38–6.06) compared to serotype 4; increasing age (25-44 
years, OR 1.75, 95% CI 1.03–2.95; 45-64 years, OR 3.56, 95% CI 2.00–6.35; ≥65 
years, OR 5.17, 95% CI 1.89–14.14; compared to 15-24 years); living in provinces 
with intermediate (OR 1.65, 95% CI 1.16–2.35) or high poverty rates (OR 1.72, 
95% CI 1.02–2.92) compared to provinces with low poverty rates; having 
meningitis (OR 4.07, 95% CI 2.98–5.55) compared to bacteremia; prior antibiotic 
treatment in the last two months (OR 3.93, 95% CI 2.50–6.20); inappropriate 
antibiotic treatment (OR 2.37, 95% CI 1.74–3.22) and positive HIV status (OR 
1.69, 95% CI 1.04–2.75).  
 
Conclusion 
 
Serotypes associated with increased mortality are included in the 10-and-13-valent 
pneumococcal conjugate vaccine and may be expected to become less common 
in adults as a result of indirect effects following routine immunization in infants. 
HIV-infected adults experience increased mortality and the more widespread 
availability of antiretroviral therapy is likely to substantially improve the quality of 
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life of HIV-infected individuals in terms of physical and mental health and decrease 
the incidence of IPD and therefore mortality. 
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CHAPTER 1 
 
INTRODUCTION 
 
This chapter gives an overview of the burden of invasive pneumococcal disease 
and its public health importance. This chapter also includes the statement of the 
problem, justification for the study, objectives of the study and a literature review. 
This study is a secondary retrospective analysis of cross-sectional data to 
determine the association between serotypes and mortality among adults with 
IPD, adjusting for confounders, in South Africa using national surveillance data 
from 2003 to 2008.  
 
1.1 Background 
1.1.1 Organism 
 
Streptococcus pneumoniae is a bacterium that causes illnesses that range from 
mild ear infections to more severe invasive pneumococcal disease (IPD) (1). In 
most cases, S. pneumoniae resides in a harmless carriage state in the 
nasopharynx of healthy individuals. Therefore, the progression from colonization to 
invasive disease is a relatively rare event (2). The acquisition and the colonization 
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of the mucosal surface of the host by S. pneumoniae followed by the invasion of 
the respiratory tract and bloodstream leads to IPD (2;3). 
 
1.1.2 Pneumococcal disease 
 
IPD remains a major cause of mortality and morbidity worldwide (1;4). IPD is 
defined as S. pneumoniae isolated from normally sterile body site specimens, and 
includes meningitis and bacteremia. Incidence, severity and mortality of IPD are 
influenced by host- and organism-related factors. The host-related factors include 
extremities of age, underlying chronic illness and immunosuppression (5-9). 
Organism-related factors include the polysaccharide capsule which is the basis for 
determining the serotype (10;11). 
 
1.1.3 Polysaccharide capsule 
 
The polysaccharide capsule of S. pneumoniae is a virulence factor (12). It is a 
highly hydrated shell that surrounds the bacterium. The polysaccharide capsule 
aids the bacterium in resisting phagocytosis and modulates the movement of ions 
and molecules to the cell envelope of the bacterium (13). The cell wall 
components and toxins such as autolysin, peptidoglycan, lipoteichoic and 
pneumolysin are known to play a role in the inflammatory response to 
pneumococcal disease (13;14). 
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1.1.4 Serotypes 
 
The chemically and serologically distinct polysaccharide capsule of S. pneumoniae 
determines the serotype (15). There are 93 known pneumococcal serotypes 
(16;17). The capsule is covalently linked to the surface of the cell-wall 
peptidoglycan which represents a virulence determinant and protects S. 
pneumoniae against phagocytic clearance (18;19). The different serotypes display 
variations with regard to their resistance to phagocytosis (20). Therefore, certain 
serotypes of S. pneumoniae tend to have greater invasive potential than others. 
Serotypes 3, 6B, 14, and 23F were found to cause more severe meningeal 
inflammation than serotypes 1, 5, 9 and 7F in experimental studies (21;22). In a 
murine model of pneumococcal sepsis, serotypes 3, 6A and 6B were more lethal 
than others (23). Serotypes also differ in their prevalence, age distribution, ability 
to cause outbreaks (24), and in antibiotic resistance (25).  
 
The reference method for serotyping of S. pneumoniae is the Quellung reaction 
(26). Several alternative methods are also used for serotyping S. pneumoniae. 
These include protein A-mediated staphylococcal (27-29), latex agglutination (30) 
the dot blot method (31) and the Ouchterlony method (32). However, conventional 
serotyping is difficult and cannot be performed on culture-negative specimens. 
Conventional polymerase chain reaction (PCR) assays, targeting serotype-specific 
genes are used for serotyping clinical specimens (33;34). Real-time PCR is faster 
and more sensitive (35). More recently, a sequential triplex real-time PCR assay 
for detecting 21 pneumococcal capsular serotypes has been developed. Some of 
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the advantages of the triplex real-time PCR assay include greater sensitivity and 
containment, where amplification products are not potential contaminants for 
subsequent PCRs (36). 
 
1.1.5 Treatment 
 
The recommended empiric treatment for pneumonia in South Africa is dependent 
on age and infecting organism and co-morbid illness. Young adults aged 65 years 
or less with no comorbid illness should be treated with intravenous penicillin 
G/ampicillin and a macrolide/azalide or a flouroquinolone (37). Adults aged 65 
years or older and/or with a comorbid illness should be treated with 
amoxycillin/clavulanate and a macrolide/azolide or a fluoroquinolone. If the patient 
presents with severe illness an additional agent should be included in the regimen. 
According to the Essential Drug List (EDL) the recommendation for empiric 
treatment for meningitis is based on age. For adults the recommendation is 
penicillin G/ceftriaxone/cefotaxime. For resistant pneumococcal meningitis, 
ceftriaxone should be used with vancomycin/moxifloxacin/rifampicin (38). 
 
1.1.6 Pneumococcal vaccines 
 
There are four commercially available pneumococcal vaccines. These include the 
23-valent pneumococcal polysaccharide vaccine (PPSV-23) consisting of 23 
capsular polysaccharide serotypes, (39) and the pneumococcal conjugate 
vaccines (PCV-7, PCV-10 and PCV-13). 
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The 23-valent pneumococcal polysaccharide vaccine (PPSV-23) consists of 23 
capsular polysaccharide serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. PPV-23 is stimulates T cell 
independent response. However, the T cell-independent response is not 
completely developed in children less than 2 years of age (40). Therefore PPSV-
23 is recommended for individuals aged 2 years and older who have underlying 
conditions and are at increased risk of IPD. It is also recommended for use in older 
adults aged 65 years and older (39;41). The only available guideline for adult 
pneumococcal vaccination with PPSV-23 in South Africa was published in 1999 
(42). However, a double-blinded randomized control trial in Uganda conducted by 
French et al (43) showed that all-cause pneumonia was significantly more frequent 
in the vaccine arm (HR 1·89, 95% CI 1·1-3·2) compared to the placebo arm and 
mortality was unaffected by PPSV-23 vaccination. This suggests that vaccination 
of HIV-infected individuals with PPSV-23 has little or no public health value in sub-
Saharan Africa. A six year follow-up of the clinical trial participants by Watera et al 
(44) confirmed the excess of all-cause pneumonia in PPSV-23 recipients (HR 1.6, 
95% CI 1.0-2.4).  
 
The PCV-7 vaccine is a preparation of capsular polysaccharide from the 7 
serotypes (4, 6B, 9V, 14, 18C, 19F, 23F) that commonly infect children, 
conjugated to a nontoxic diphtheria cross-reactive material carrier protein 
(CRM197) which results in enhanced serum antibody response as well as eliciting 
a T cell-dependent memory (booster) response (45). PCV-10 contains the seven 
serotypes included in PCV-7 and three additional serotypes (1, 5 and 7F). PCV-13 
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contains the seven serotypes in PCV-7 and six additional serotypes (1, 3, 5, 6A, 
7F and 19A). PCV-7 and PCV-13 are recommended for use among children from 
age 6 weeks to less than 6 years. PCV-10 is recommended for persons up to two 
years of age (39). In April 2009, PCV-7 was introduced into the Expanded 
Programme on Immunization (EPI) in South Africa. This was followed by the 
introduction of PCV-13 in July 2011. The schedule followed for both PCV-7 and 
PCV-13 in South Africa is vaccination at 6 weeks, 14 weeks and 9 months of age.  
 
 Studies in the U.S. have shown the effectiveness of one or more doses of PCV-7 
against vaccine serotypes (as well as 6A as a result of cross protection ) to be 
96% (95% CI 93-98) in healthy children and 81% (95% CI 57-92) in children with 
underlying illnesses (46). Using an indirect cohort design, Andrews et al (47) used 
enhanced surveillance data from the Health Protection Agency in the U.K. to show 
increasing effectiveness of PCV-7 from 56% (95% CI -7-82) for a single dose to 
93% (95% CI 70-98) for two doses plus a booster dose in the second year of life. 
In addition, Pićon et al (48) conducted a case-control study in Uruguay which 
showed a 91.3% (95% CI 46.4-98.6) vaccine effectiveness of PCV-7 for one or 
more doses and 94.8% (95% CI 43.1-99.5) for two or more doses.  
 
1.1.7 Surveillance of pneumococcal disease in South Africa  
 
A major event in South Africa was described by Brodie et al (49) where 93 mine 
workers arrived at a mine in mid-winter and after two weeks only 16 miners were 
able to work as the remaining miners had contracted respiratory tract infections, 
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including pneumonia. Eight of the miners died, following which winter employment 
of miners from tropical countries was banned. In 1912, the South African Institute 
for Medical Research (SAIMR) was established. This was prompted by major 
outbreaks of pneumonia among miners as well as other infectious diseases with 
high mortality rates, such as meningococcal meningitis (50).  
 
Klugman et al (51) analyzed 4766 strains of S. pneumoniae isolated from blood 
and 1157 isolates from cerebrospinal fluid (CSF) from 1979 to 1986. Results 
showed that resistance increased among isolates from blood (3.8% to 14.1%) and 
CSF (6.8% to 14.1%). In addition, 19.2% of resistance strains were from strains 
belonging to serogroups 6, 19 or 14. Huebner et al (52) studied trends in 
antimicrobial resistance in pneumococci isolates (blood and CSF) between 1991 
and 1998 in South Africa. Multiple drug resistance increased significantly from 
2.2% to 3.8%. The percentage of serogroups found in the nonavalent 
pneumococcal conjugate vaccine (1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F) 
increased significantly from 72% to 91% over the study period.  
 
In 1999, Dr Robyn Huebner and colleagues introduced a national laboratory-based 
surveillance system for IPD in South Africa. Laboratories were requested to send 
isolates and reports of laboratory-confirmed IPD cases to the National Institute for 
Communicable Diseases (NICD) in Johannesburg (53). The system was 
enhanced in 2003, resulting in an active surveillance system with improved 
communication and site visits to improve the reporting of cases. Additional clinical 
and demographic information was collected (54). This national laboratory-based 
8 
 
surveillance system is ongoing and provides a wealth of information for evaluating 
burden of disease, health risks and health interventions.  
 
1.2 Statement of the problem  
S. pneumoniae is a common cause of pneumonia, meningitis, septicemia and 
otitis media. It is associated with significant morbidity and mortality worldwide. 
Since the introduction of PCV-7, studies have shown a decline in prevalence of 
IPD in vaccinated children and unvaccinated adults (55). However, a significant 
burden of disease exists worldwide due to serotypes that are not included in PCV-
7 (56). Previous international studies have shown an association between 
pneumococcal serotypes and disease outcome, particularly mortality in adults 
(57;58). These associations could differ in a developing country such as South 
Africa, where there is a higher HIV prevalence and a greater diversity of serotypes 
associated with IPD (5;59). von Gottberg et al (54) conducted active laboratory-
based, national surveillance for IPD in children <5 years in South Africa to 
determine the epidemiology of IPD in the pre-conjugate vaccine era. Results 
showed that 58%, 65% and 85% of cases and 61%, 64% and 82% of deaths were 
caused by serotypes included in PCV-7, PCV-10 and PCV-13, respectively. It was 
also shown that compared to serotype 14, serotypes 18C and 8 were more likely 
to cause meningitis and serotypes 6A, 19A and 16 were more likely to cause 
bacteremia. Furthermore, compared to serotype 14, serotypes 6B, 18C, 1, 5 and 8 
were significantly less likely to be associated with HIV-infected children (54). It 
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would be interesting to see if similar observations are made in an adult population 
in South Africa.  
 
1.3 Justification for this study 
There are no studies to date in South Africa that have looked at the association of 
serotypes with mortality amongst adults with IPD. In addition, few studies were 
able to determine the association between serotypes and mortality in the absence 
of potential effects of pneumococcal vaccination (58). The study population of this 
study included adult patients with IPD from 2003 to 2008, which was prior to the 
widespread introduction of PCV-7 and PCV-13 in South Africa. Understanding 
serotype-specific disease outcome provides knowledge with regard to the potential 
benefits of vaccines with serotypes that are associated with increased mortality 
(57). Therefore, results of this study will provide insight when planning health 
interventions to control mortality associated with IPD in South Africa. 
1.4 Literature review  
1.4.1 Serotype epidemiology 
1.4.1.1 Association of serotypes with carriage and IPD  
 
Serotypes associated with nasopharyngeal carriage include most of the serotypes 
found in PCV-7 (except serotype 4), serotype 6A, 19A, 3 and 7F (24). Of the 
known serotypes, a small number cause the majority of invasive disease (5;60). 
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Regev-Yochay et al (61) compared the rate of S. pneumoniae carriage among 
adults with that among children ≤6 years from 50 primary care clinics in Israel. S. 
pneumoniae carriage rates differed significantly between adults and children. The 
most common serotypes among adults were 6A, 14, 6B, 33F, 11A, 3 and 10, 
which accounted for 47.4% of all isolates from adults and 24.1% of all isolates 
from children (p=0.02). The most frequently isolated serotypes among children 
were 6B, 19F, 23F, 6A, 14, 35B and 23A, which accounted for 53.1% of all 
isolates and only 26.3% of all isolated from adults (p=0.01). Adetifa et al (62) 
performed a cross sectional survey to describe pneumococcal carriage in Nigeria. 
Carriage was higher in children (67.4%) compared to adults (26%), was highest in 
infants <9 months and reduced significantly with age (p<0.001). The most 
common serotypes were 19F (18.6%) and 6A (14.4%). 
 
Hausdorff et al (5) conducted a review of 73 international studies and showed that 
serotypes vary depending on geographic location and patient age over time, 
although serogroups 1, 6, 14, 19 and 23 were predominant in every region. 
Serotypes 12F, 8, 22F, 15A, 15B and 11A caused a large proportion of disease in 
the older (adult) age groups (5). In addition, serotypes 1 and 3 were associated 
with severe disease regardless of age and other factors contributing to disease 
severity (63). Brueggemann et al (64) compared 150 S. pneumoniae isolates 
causing invasive disease to 351 nasopharyngeal carriage isolates in children <5 
years in Oxford. Results showed that serotypes 1, 4 and 7F were associated with 
a high level of invasiveness. Serotypes 1, 4, 7F and 9V were also found among 
the invasive isolates in a study performed in Stockholm, Sweden where 273 
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invasive isolates (257 from adults and 16 from children) and 246 nasopharyngeal 
isolates were analyzed by serotyping and molecular serotyping (65). This indicates 
that these pneumococcal serotypes, although less common among carriers, had a 
high capacity of causing invasive diseases as compared to other serotypes 
(64;65).  
 
A more recent meta-analysis of serotypes causing IPD among children <5 years of 
age showed that serotype 14 was the most common in every region and serotypes 
1, 5, 6A, 14 19F and 23F were the cause of more than 50% of IPD in every region. 
Serotype 1 was predominant in Asia, Africa and Europe indicating that this 
serotype is not only common in developing countries (60). A prospective 
observational cohort study was conducted in a large UK hospital over two years in 
patients ≥16 years of age with community-acquired pneumonia. Results indicate 
that the most prevalent serotypes in the cohort were serotypes 14 (n=45), 1 
(n=40), 8 (n=35), 3 (n=20) and 19A (n=20) (66). Another study conducted in 
Portugal to determine the serotype and antimicrobial susceptibility of 1265 S. 
pneumoniae isolates in adult patients with IPD between 2009 and 2011. The 
results were compared to previously published data from 1999 to 2008. It was 
shown that serotypes 3 (12.6%), 7F (10.0%), 19A (9.1%), 14 (8.4%), 1 (6.9%) and 
8 (6.2%) were the most common serotypes which accounted for 53.2% of adult 
IPD. Serotype 1 decreased from 10.7% to 4.1% and serotype 5 decreased from 
2.0% to 0% during the study period (2009-2011) (67). Imohl et al (68) evaluated 
the association of serotypes of S. pneumoniae with age in IPD in Germany from 
1992 to June 2006. 54.0% of the isolates were from adults ≥16 years of age and 
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46.0% were from children <16 years of age. Serotypes 3 and 4 were more 
common in adults while serotypes 14, 6B, 19F and 18C were predominant in 
children.  
 
1.4.1.2 Association of serotypes with HIV 
Hausdorff et al (24) analyzed data from six studies from Africa and North America 
and demonstrated that HIV-infected adults have more infections with the serotypes 
present in PCV-7. Studies also showed that the association between the pediatric 
serotypes and IPD in HIV-infected adults was not a result of increased antibiotic 
resistance alone (69;70). Moreover, studies also show that HIV-infected women 
were at greater risk of disease caused by the pediatric serotypes as compared to 
HIV-infected men. This could be attributed to the fact that mothers are more likely 
to come into contact with pediatric carriers of pneumococci (71). 
 
1.4.2 Risk factors for mortality in adults with IPD 
1.4.2.1 Association of pneumococcal serotypes and mortality 
 
A systematic review and meta-analysis of 9 studies by Weinberger et al (57) 
determined the association of serotype with risk of death due to IPD. Results 
suggested that among adult patients presenting with bacteremic pneumonia, the 
risk of death varies by serotype. However, this was not seen among meningitis 
patients. Serotypes 1, 7F, and 8 were associated with decreased risk ratios (RRs) 
of death while serotypes 3, 6A, 6B, 9N and 19F were associated with increased 
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RRs of death. In addition, it was found that serotypes with increased RRs of death 
had a higher carriage prevalence and low invasiveness.  
 
A retrospective cohort study by Jansen et al (58) using nationally representative 
surveillance data from 1075 hospitalized adult patients with IPD in the Netherlands 
from 1 June 2004 to 31 May 2006 attempted to determine the association among 
serotypes, disease characteristics and outcome among adult patients with IPD. 
The serotypes were grouped according to those with a low (1, 5, 7F, 15B, 20 and 
33F), intermediate (4, 6A, 8, 9V, 10A, 11A, 12F, 14, 19A, 22A, 22F, 23F and 24F) 
and high case-fatality ratios (CFR) (3, 6B, 9N, 16F, 18C, 19F and 23A). On 
multivariable analysis, in comparison to the low-CFR reference group of serotypes, 
the group of serotypes 3, 6B, 9N, 16F, 18C, 19F and 23A were associated with 
increased CFR (odds ratio [OR] 2.6, 95% confidence interval [CI] 1.5-4.7). These 
results indicate that the serotypes were independently associated with outcome of 
IPD in adults (58).  
 
A more recent study by van Hoek et al (72) investigated the effect of serotype on 
clinical presentation and outcome from IPD in all ages after the introduction of 
PCV-7 and PCV-13. Results indicated that there were significant differences 
between serotypes in the ability to cause meningitis and mortality. Serotypes 31 
(CFR of 33%), 11A (CFR of 30%) and 19F (CFR of 21%) had the highest CFR 
amongst the 5 to 64 years age group. In addition, serotypes 3, 19F, 19A, 6A, 9N, 
11A and 31 were associated with higher mortality as compared to serotype 14 
(8%) in the 5 to 64 years age group. Nyasulu et al (73) determined the risk factors 
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for mortality in South African children <5 years of age with IPD. Results showed no 
association between childhood serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) and 
risk of death. 
 
1.4.2.2 Age as a risk factor for mortality 
 
Kothe et al (74) conducted a prospective multicentre study initiated by the German 
Competence Network for Community-Acquired Pneumonia to assess the risk 
factors influencing community-acquired pneumonia mortality. Overall mortality was 
significantly higher among elderly patients, ≥65 years (10.3%) than in the younger 
age group, <65 years (2.2%; p<0.001).  
 
In a prospective cohort study of 404 patients in the USA, Waterer et al showed 
that increasing age (41 to 80 years) was independently associated with medium-
term mortality (75). In addition, Feikin et al (6) used a population-based, active 
surveillance in North America to assess the epidemiologic factors affecting 
mortality from pneumococcal pneumonia. Results indicate that increased mortality 
was associated with increased age (18-64 years, OR 5.1, 95% CI 1.2-21.0; 65-74 
years OR 5.8, 95% CI 1.4-25.0; ≥75 years, OR 12, 95% CI 2.8-49.0) compared to 
≤17 years of age. 
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1.4.2.3 Underlying medical conditions, including HIV as a risk factor for 
mortality 
 
van Hoek et al (76) conducted a study in England where over 22 000 IPD patients 
aged two years and over were linked to hospital records. Among IPD patients 
aged 16-64 years, increased odds of developing IPD was associated with liver 
disease (OR 33.3, 95% CI 30.7-36.1); immunosuppression (OR 17.1, 95% CI 
16.0-18.3) and HIV (OR 61.2, 95% CI 51.3-72.9). In addition, within each age-
group, the CFRs were higher for those with underlying medical conditions 
compared to those without underlying medical conditions (OR 2.5 in children, 95% 
CI 1.2-5.1; OR 3.9 in 16-64 year olds, 95% CI 3.4-4.4; OR 1.2 in ≥65 year olds, 
95% CI 1.1-1.3). However, no deaths were seen in the HIV groups as the numbers 
were too small.  
 
As mentioned previously, Feikin et al (6) used population-based, active 
surveillance in North America to assess the epidemiologic factors affecting 
mortality from pneumococcal pneumonia. Results show that increasing mortality 
was independently associated with underlying medical conditions (OR 2.8, 95% CI 
2.0-3.9). In addition, Klemets et al (77) used population-based data reported by 
Finnish clinical microbiology laboratories to determine risk of mortality associated 
with underlying medical conditions in patients with IPD. The highest hazard ratios 
were seen in patients with alcohol-related disease (HR 5.6, 95% CI 3.8-8.1); HIV-
infection (HR 4.8, 95% CI 2.1 -10.9) and non-hematological malignancy (HR 4.7, 
95% CI 3.3-6.7). 
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Renee et al (78) conducted a chart review of 147 hospitalized HIV-infected and 
HIV-uninfected IPD patients in New England to characterize epidemiologic and 
clinical features, serotypes, as well as antibiotic susceptibility patterns. Mortality 
rates did not differ by HIV status [13% (n=38) in HIV-infected versus 12% (n=115) 
in HIV-uninfected] even after controlling for age.  
  
The burden of pneumococcal disease among adults and older children in Africa, 
with a high HIV prevalence setting, has not been well established. A prospective 
cohort study by Feikin et al (79) in western Kenya showed a high burden of 
pneumococcal bacteremia amongst individuals ≥5 years of age. It was also found 
that the extrapolated rate of pneumococcal bacteremia among HIV- infected adults 
(≥18 years of age) was 2399 per 100 000 person-years as compared to 122 per 
100 000 person-years in HIV- uninfected adults (rate ratio 19.7, 95% CI 12.4–
31.1). Studies by Cohen et al performed in the US after PCV-7 and highly-active 
antiretroviral treatment (HAART) introduction, showed that incidence of IPD in 
HIV-infected adults was 40-times higher than the incidence of IPD in HIV-
uninfected adults (80). 
 
Jones et al (81) determined the burden of bacteremia due to S. pneumoniae in 
HIV-infected children and adults in South Africa. The incidence of bacteremia was 
8.2 times increased in HIV-infected adults and 36.9 times increased in HIV-
infected children compared to HIV-uninfected individuals.  
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1.4.3 Impact of antiretroviral therapy (ART) on IPD in South Africa 
 
In Gauteng Province, South Africa, prior to the introduction of PCV-7 into the 
public sector, Nunes et al (82) aimed to evaluate the trends in IPD hospitalizations 
in HIV-infected adults after the up-scaling of the HAART program from 2003 to 
2008. The periods 2003 to 2004, 2005 to 2006 and 2007 to 2008 were defined as 
the early-HAART era, intermediate-HAART era and established-HAART era, 
respectively (82). Despite the introduction of HAART for HIV-infected individuals, 
the burden of IPD had not decreased in adults that were HIV-infected, while IPD-
associated mortality rates in HIV-infected adults increased. Although declines in 
the burden of IPD in HIV-infected children were associated with the increased 
availability of HAART and prevention-of-mother-to-child-transmission (PMTCT), 
these children remained at a high risk for IPD-associated morbidity and mortality 
(83).  
 
Kourtis et al described national hospital trends of IPD among HIV-infected adults 
and children after HAART and PCV-7 introduction in the United Stated using a 
national inpatient cohort. Data was analyzed from 1994-1995 (pre-HAART, pre-
PCV era), 1998-1999 (HAART, pre-PCV era) and 2004-2005 (HAART, early PCV 
era). There was a 49.2% reduction in IPD hospitalizations among HIV-infected 
individuals between 1994/1995 and 2004/2005. In addition, the adjusted OR for 
IPD hospitalizations for HIV-infected individuals during 2004/2005 compared to 
1994/1995 was 0.64 (95% CI, 0.54-0.77). However, regardless of the overall 
decreases observed, the rate of IPD hospitalizations remained much higher during 
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2004-2005 among HIV-infected individuals compared to HIV-uninfected individuals 
(84). 
1.5 Study objectives 
1.5.1 To describe trends in incidence of IPD by serotype in South Africa using 
national surveillance data from 2003 to 2008.  
1.5.2 To describe the distribution of serotypes by age, HIV status, clinical 
syndrome and in-hospital outcome, among adult patients with IPD in South Africa 
using national surveillance data from 2003 to 2008.  
1.5.3 To determine the association between serotypes and mortality rates overall 
and among adults with meningitis and bacteremia separately, adjusting for 
confounders, in South Africa using national surveillance data from 2003 to 2008.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
This chapter describes the study population, data sources as well as data 
management. In addition, variables are defined and a description of the study 
hypotheses, statistical methods and data analyses are given.  
 
2.1 Study design   
This is a secondary retrospective analysis of cross-sectional data from national, 
population-based surveillance for IPD in South Africa. Although surveillance data 
could be described as cohort data as all cases within the population are collected 
on an ongoing basis, for this secondary analysis, data on the exposure and 
outcome are collected at the same point in time. The study period was from 1 
January 2003 to 31 December 2008.  
 
2.2 GERMS-SA: Primary data source 
The Group for Enteric Respiratory and Meningeal disease Surveillance in South 
Africa (GERMS-SA) (85) plays a role in describing the epidemiology and 
estimating the burden of invasive disease caused by several pathogens. 
Approximately 200 clinical microbiology laboratories in all provinces participate in 
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the program. These include private, public, mining and military laboratories. Basic 
demographic information including gender, age, specimen collection date and 
source of specimen, are collected for all cases using standardized case report 
forms (CRFs). In 2003, the surveillance system was enhanced to include 25 
sentinel enhanced surveillance sites. There is at least one enhanced surveillance 
site in each province in South Africa. Hospitals at these sites are regional, tertiary 
academic or referral centres. The National Health Laboratory Service (NHLS) 
laboratories are well resourced and have the capacity to accommodate laboratory 
testing for the sites. Information collected at enhanced surveillance sites includes 
admission date, previous antibiotic usage, HIV status, underlying medical 
conditions, discharge diagnosis and outcome for all cases. This differentiates the 
enhanced from the non-enhanced sites (85). 
 
2.3 Study population and sampling 
For the national surveillance, laboratories identify organisms under surveillance, 
and these are submitted with the laboratory reports to the NICD. Limited data are 
collected at non-enhanced sites. For the enhanced surveillance sites, the 
laboratories inform the surveillance officers who determine the patient’s location 
and informed consent is obtained from the patient, following which a case report 
form is filled in. If the surveillance officer is unable to locate the patient, or the 
patient has been discharged or has died, the surveillance officer completes the 
case report form retrospectively using the hospital record forms (85). 
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For the seasonality and outbreaks analysis the study population included adult IPD 
patients (≥15 years) presenting at enhanced and non-enhanced surveillance sites 
from 2003 to 2008. For the trend analysis the study population included adult IPD 
patients (≥15 years) with the 20 most common serotypes presenting at enhanced 
and non-enhanced surveillance sites from 2003 to 2008. For the descriptive and 
multivariable analyses the study population included all adult IPD patients (≥15 
years), with complete CRFs, known in-hospital outcome and with the 20 most 
common serotypes presenting at enhanced surveillance sites from 2003 to 2008. 
The rationale for only using the enhanced surveillance sites in this secondary data 
analysis, is that these sites include valid data on admission, in-hospital outcome, 
diagnosis and HIV status that is required for this analysis (85). The top 20 most 
common serotypes were used for the analyses as patients presenting with these 
serotypes constituted approximately 84% of the study population. The remaining 
16% of serotypes not included in the analysis constituted 51 other serotypes 
whose prevalence ranged from 0.1% to 1%. 
 
2.4 Data management 
The data for the secondary analysis was obtained from the GERMS-SA 
surveillance database which is in Microsoft-Access. Data from the enhanced 
surveillance sites was used for the analysis. The database was monitored and 
cleaned on an ongoing basis with quality assurance processes in place. Before 
analyzing, validity checks were done to ensure completeness and to identify 
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transposition, copying, consistency and range errors. This was done by performing 
frequencies and cross tabulations. Discrepancies were resolved by comparing the 
database with the hard copy of the forms. The database was then corrected 
accordingly. The variables of interest were recoded and categorized as necessary.  
 
2.5 Definitions 
All variables were defined before the data were analyzed.  
2.5.1 Main exposure of interest 
 
The main exposure of interest was serotype. The 20 most common serotypes 
were included as a categorical variable in multiple levels in the analysis. 
 
2.5.2 Additional potential confounders and risk factors 
 
 HIV status was defined as positive or negative documented form medical 
records of tests done during current or prior admission, documented by a 
clinician. 
 Disease severity was measured using the Pitt bacteremia score (86;87). 
The scores resulting from the following parameters were added to form the 
Pitt bacteremia score: 
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(i) Oral temperature: 2 points for a temperature of ≤35ºC or ≥40ºC, 1 point 
for temperature of 35.1ºC-36.0ºC or 39.0ºC–39.9ºC and 0 point for 
temperature of 36.1ºC-38.9ºC. 
(ii) Hypotension: 2 points for systolic blood pressure of less than 90 
mm Hg. 
(iii) 2 points for receipt of mechanical ventilation. 
(iv) 4 points for cardiac arrest. 
(v) Mental status: if alert 0 point; disoriented 1 point; stuporous 2 points and 
comatose 4 points (87). 
Acute severe illness was defined as a Pitt bacteremia score of >4 at the 
time of specimen collection. 
 
 Age-group: Adult patients were categorized into 4 groups. These include 
15-24 years, 25-44 years, 45-64 years and ≥65 years. 
 
 Disease syndrome: Pneumococcal meningitis diagnosis was defined by a 
positive CSF culture or a positive blood culture and clinical diagnosis of 
meningitis. Pneumococcal pneumonia diagnosis was based on clinician 
diagnosis of pneumonia with a positive blood or pleural fluid culture (85). 
Pneumococcal bacteremia without focus was defined by a positive blood 
culture that had no other known focus of infection (58;88). 
 
 Nosocomial infection was defined as the specimen collection date ≥2 days 
after hospital admission date. 
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 Prior antibiotic use (prior 24 hours) was defined as any antibiotic use 24 
hours prior to specimen collection. 
 
 Prior antibiotics use (past two months) was defined as use of any antibiotics 
within two months preceding specimen collection. 
 
 Underlying medical conditions were defined as asplenia, sickle cell anemia; 
chronic illnesses including lung , liver, renal, cardiac disease and diabetes; 
other immunocompromising conditions including malignancy, primary 
immunodeficiency, immunotherapy and organ transplant; as well as other 
Advisory Committee on Immunization Practices (ACIP) (89) risk factors 
including head injury with CSF leak, alcohol and smoking. Other risk factors 
include prematurity, neurological conditions, chromosomal abnormalities 
and burns. We used a binary variable consisting of the absence or 
presence of any underlying condition. 
 
 Gender was defined as either male or female sex. 
 
 Province was grouped into 3 categories based on poverty rates (low, 
intermediate and high) from the Findings of the living conditions survey 
2008/2009 conducted by Statistics South Africa (90). The low poverty rate 
group consisted of Gauteng and Western Cape. The intermediate poverty 
rate group consisted of KwaZulu-Natal, Free State, Northern Cape and 
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North West. The high poverty rate group consisted of Eastern Cape, 
Mpumalanga and Limpopo. This survey was used as it covers a wide range 
of indicators including household income, household expenditure, minimum 
income, ownership of assets, self-perceived poverty status as well as 
access to services and facilities. 
 
 Race was grouped into “Black” and “other”, where “other” consisted of 
White, Asian and Colored.  
 
 Isolates defined as either intermediately or resistant to penicillin were 
regarded as non-susceptible using the conservative Clinical and Laboratory 
Standards Institute meningeal breakpoints (91). 
 
 Multi-drug resistance was defined as non-susceptibility to any three or more 
different antibiotic classes, according to the 2009 definitions of the Clinical 
and Laboratory Standards Institute (91). 
 
 Vaccine serotype was defined as the 13 serotypes found in the PCV-13 
vaccine i.e 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. 
 
 Appropriate antibiotic use: data on the antibiotics used for data 
management was compared with the recommended antibiotic guidelines to 
determine whether the appropriate antibiotic was administered to the 
patient (Table 2.1) (92).
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Table 2.1: Criteria to determine appropriate antibiotic use 
Antibiotic * Meningitis Pneumonia or 
Bacteremia 
Other # 
1st gen cephalosporin 
(cefalexin, cefazolin, 
cefradine) 
Inappropriate Appropriate Appropriate 
2nd gen cephalosporin 
(cefaclor, cefoxitin, 
cefuroxime,  cefprozil) 
Inappropriate Appropriate Appropriate 
3rd gen cephalosporin 
(cefotaxime, 
ceftazidime, 
ceftriaxone, 
cefpodoxime) 
Appropriate Appropriate Appropriate 
4th gen cephalosporin 
(cefepime) 
Appropriate Appropriate Appropriate 
Imipenem Appropriate Appropriate Appropriate 
Meropenem Appropriate Appropriate Appropriate 
Piperacillin Inappropriate Appropriate Appropriate 
Tazobactam Inappropriate Appropriate Appropriate 
Amoxicillin Inappropriate Appropriate Appropriate 
Augmentin Inappropriate Appropriate Appropriate 
Erythromycin  Inappropriate Appropriate Appropriate 
 
*Other antibiotics and antifungal agents that were not used to create appropriate antibiotic 
variable include: amikacin, amphotericin B, chloramphenicol, cipromycin, clindamycin, 
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cloxacillin, cotrimoxazole (for therapeutic and prophylactic use), flagyl, fluconazole, 
gentamicin, nalidixic acid, ofloxacin, streptomycin, tetracycline, vancomycin. These 
antibiotics and antifungal agents were excluded as they are not used individually for the 
treatment of IPD. 
#Other illnesses include bacteremia without focus and pneumococcus isolated from other 
sterile sites (joint aspirate, pleural fluid, peritoneal fluid). 
 
2.5.3 Outcome 
 
Final outcome of the patient was defined as the patient’s in-hospital outcome. 
Mortality was defined as death within 30 days from the first positive result for S. 
pneumoniae. IPD is a severe acute bacterial infection and patients usually die 
within a day or two of hospitalization (73). If the patient died after 30 days of 
positive S. pneumoniae result, it is likely that the patient died from other causes. 
The final outcome variable was binary including “died” and “survived.” The 
“survived” category consisted of discharged, transferred, and refused hospital 
treatment. “Refused hospital treatment” was defined as patients who either 
refused admission or refused ongoing care in hospital. These patients were given 
medication before being sent home. The likely outcome of such cases is that they 
survived. 
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2.6 Laboratory methods 
2.6.1 Pneumococcal serotyping 
 
Pneumococcal serotypes were serotyped by capsule swelling known as the 
Quellung reaction resulting from the interaction between the pneumococcal 
capsular polysaccharide and its homologous antibody (93). The pneumococci are 
typed further by a capsular reaction test using the “Chess-board Method” where 
pneumococcal groups/types react with one or two pooled antisera. Once a positive 
reaction is obtained with the pooled antisera, individual group and serotype-
specific antisera included in the pooled antisera are tested to determine the 
serogroup and serotype (94).  This was done using sera from the Statens Serum 
Institut (SSI), Copenhagen, Denmark (95).  
 
2.7 Statistical methods and data analysis 
 
All available data were used for the analysis. The data from Microsoft-Access was 
exported into Microsoft-Excel 2003 and analyzed using STATA version 12; Stata 
Corp, College Station, TX.  
 
Proportions and frequencies were used for the descriptive statistics. Significant 
trends in incidence by serotype were assessed using Poisson regression as it 
quantifies increases or decreases in incidences and gives p values, indicating 
statistical significance. Seasonality and outbreaks was assessed by evaluating the 
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incidence of IPD cases by year and month. To assess the association between 
serotypes and age, HIV co-infection, clinical syndrome and in-hospital outcome for 
each serotype compared to serotype 4 (the serotype which is third most common 
serotype (289/3953, 7% and had an intermediate CFR of 29%), we used 
univariate multinomial regression models and generated a separate estimate of 
effect for each predictor on each outcome relative to the base level. The effect 
measures are the relative risk ratios (the ratios of two relative risks) where each 
relative risk describes the probability of the outcome in the category of interest 
relative to the baseline category (96).  
 
Descriptive statistics was reported by means of tables and graphs. For the 
inferential statistics, univariate analysis was done using logistic regression, where 
crude OR was calculated (with 95% CI and p values). Univariate logistic 
regression was done to assess differences between enhanced and non-enhanced 
surveillance site data. If patients from enhanced sites differ substantially from 
patients presenting at non-enhanced sites, this could affect generalizability of the 
findings.  
 
Univariate logistic regression was done to assess the risk factors (variables) 
associated with mortality. Multivariable logistic regression was then done to 
evaluate the risk factors that were statistically significant, p <0.1 in the univariate 
analysis. This was done using stepwise forward selection and backward 
elimination. Inferential statistics were reported by means of tables. Potential 
confounders were controlled for in the multivariable regression model. All 
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statistical tests excluded missing values. In this study, p<0.05 in the multivariable 
analysis was considered statistically significant. 
 
2.8 Ethical approval 
The GERMS-SA obtained ethical clearance from the Human Research Ethics 
Committee (Medical), University of Witwatersrand Johannesburg (M081117: 
GERMS-SA: Provision of Strategic Information through Laboratory-based 
Surveillance for AIDS-associated Bacterial and Fungal Opportunistic Infections in 
South Africa: Meeting date 28 November 2008 – renewed annually in 2009 and 
2010). Ethics clearance was also obtained from the relevant University and 
Provincial Ethics Committees for the enhanced surveillance sites. Ethics approval 
was obtained from the Human Research Ethics Committee (Medical), University of 
Witwatersrand for this secondary analysis (M121050). 
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CHAPTER 3 
Results 
 
This chapter gives an in depth explanation of the results found in the secondary 
data analysis. 
3.1 Overview 
From January 2003 through December 2008 we identified 27632 patients of which 
15105 had known age and were aged ≥15 years (55%) (Figure 1). Of these, 8962 
were ≥15 years presenting with the 20 most common serotypes. These patients 
were included in the serotype trend analysis.   
 
Of the 15105 patients, 7329 (49%) patients presented at enhanced sites, of which 
3407 (46%) were male, 3895 (53%) were female and 27 (1%) were unknown. 
2684 patients had known HIV status of which 2401 (89%) were HIV-infected and 
283 (11%) were HIV-uninfected. Of the HIV-infected patients 180 (8%) were on 
ART. Of the 7329 patients presenting at enhanced sites, 6061 patients had a 
clinical record review of which 6021 (99%) had a known in-hospital outcome.  
 
We included 3953 (84%) patients in the univariate and multivariable analysis of 
risk factors for mortality that had viable isolates, had known outcome, completed 
case report forms and presented with the 20 most common serotypes. Of these 
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patients, 1807 (46%) were male and 2146 (54%) were female and the median age 
was 36 years. HIV-infected patients constituted 89% (2309/2580), while HIV-
uninfected patients constituted 11% (271/2580) of the study population with known 
HIV status. Of the HIV-infected individuals, 51% (1184/2309) had a CD4+ counts 
of <200 cells/µL and 178 (8%) were on ART. In addition, the prevalence of HIV 
was highest among individuals 25-44 years of age (1688/2309, 73%). The 
prevalence of nonsusceptibility to penicillin was 28% (1089/3953). The majority 
(99%; 1081/1089) of these isolates displayed intermediate resistance to penicillin, 
with only 1% (8/1089) showing high-level resistance. The prevalence of multi-drug 
resistance was 15% (609/3953). 
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Figure 1: Flow chart of patients enrolled in GERMS-SA from 2003-2008 and included in the 
analysis.*Pneumococci that did not have a capsule and could not be serotyped. # Isolates from 
patients that were infected with two strains of pneumococci with different serotypes from the same 
patient. 
27632 patients in total 
7329 from enhanced sites (49%) 7776 from non-enhanced 
sites (51%) 
1268 with no clinical 
record review (17%) 
6061 with clinical record 
review (83%) 
40 unknown outcome (1%) 6021 known outcome (99%) 
1324 non-viable isolates 
(22%) 
4697 viable isolates 
(78%) 
*5 non-typeable isolates (0.11%) 
#
5 mixed infections (0.11%) 
 
4687 patients (99.79%) 
734 patients presenting 
with infrequent 
serotypes (16%) 
 
3953 patients 
presenting with the 
20 most frequent 
serotypes (84%) 
(including PCV-13 
vaccine serotypes) 
 
11173 (40%) patients less than 
14 years of age and 1354 (5%) 
missing age 
 
15105 with known age and 
age ≥ 15 years (55%) 
8962 ≥15 years with 
20 most common 
serotypes (trend 
analysis) 
Univariate analysis 
comparing patients at 
enhanced versus 
non-enhanced sites 
Descriptive analysis 
and multivariable risk 
factor analysis 
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3.2 Serotype changes over time 
Over the study period there were 8962 patients ≥15 years presenting with the 20 
most common serotypes. The incidence of serotypes 4 (p<0.001); 19A (p<0.001); 
23F (p=0.003) and 18C (p=0.002) increased significantly from 2003 to 2008. The 
incidence of serotype 1 (p<0.001); 25 (p=0.001) (97) and 5 (p=0.042) decreased 
significantly over the study period (2003-2008) (Figure 2).  
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Figure 2: Incidence of invasive pneumococcal disease among persons 15 years and older by the top 20 serotypes causing 
disease, GERMS-SA, 2003-2008 (n=3988) *Significant increase in trends, broken lines. #Significant decrease in trends, broken 
lines. 
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3.3 IPD seasonality and outbreaks  
Over the study period there were 15105 patients ≥15 years of age presenting with 
IPD caused by all serotypes at enhanced and non-enhanced sites (Figure 3). IPD 
exhibited seasonal variations with the peak incidences during the winter months 
(May to August). When restricted to the top 20 most common serotypes the 
seasonal variations of IPD incidences were similar to that of all serotypes causing 
IPD (data not shown). There was no evidence of obvious outbreaks during the 
study period. 
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Figure 3: Seasonality of invasive pneumococcal disease among persons 15 years and older by all serotypes causing 
disease, GERMS-SA, 2003-2008.    
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3.4 Distribution of IPD serotypes by age group, HIV status, syndrome and 
mortality 
We chose serotype 4 as the reference group as it is the third most common 
serotype (289/3953, 7%) and has an intermediate CFR (29%). There was no 
significant difference in the distribution of serotype 4 amongst the different age-
groups (p=0.792), HIV status (p=0.812), clinical diagnosis (p=0.265) and CFRs 
(p=0.062). Analyzing the 20 most common serotypes, using multinomial 
regression, comparing the age distribution of all other serotypes to the age 
distribution of serotype 4 (25-44 years as the referent group), serotype 3 was 
significantly more likely to be identified from patients 45-64 years of age (relative 
risk ratio [RRR] 1.88, 95% CI 1.26-2.81, p=0.003), serotype 1 was significantly 
more likely to be isolated from patients 15-24 years of age (RRR 1.79. 95% CI 
1.15–2.80, p=0.010) and serotype 19F was significantly more likely to be isolated 
from patients 45-64 years of age (RRR 1.64 95% CI 1.05–2.56, p=0.030) (Figure 
4). 
 
Compared to serotype 4, serotypes 12F (RRR 3.12, 95% CI 1.05-9.31, p=0.041) 
and 9V (RRR 11.99, 95% CI 1.59-90.30, p=0.016) caused significantly more 
disease in HIV-infected individuals and serotype 1 (RRR 0.50, 95% CI 0.30-0.83, 
p=0.008) was significantly less likely to be identified in HIV-infected patients 
(Figure 5). Serotypes 19A, 3, 6A, 14, 23F, 12F, 9N, 7F, 18C, 25, and 5 differed 
when compared to serotype 4 by clinical syndrome. Serotypes 6A (RRR 1.47, 95% 
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CI 1.03-2.10, p=0.032) , 23F (RRR 1.59, 95% CI 1.11-2.28, p=0.011), 12F (RRR 
1.77, 95% CI 1.18-2.65, p=0.005), 18C (RRR 2.15, 95% CI 1.20-3.84, p=0.010) 
were more likely to cause meningitis, while serotypes 19A (RRR 2.24, 95% CI 
1.58-3.17 p<0.001), 3 (RRR 3.31, 95% CI 2.14-5.12, p<0.001), 14 (RRR 2.10, 
95% CI 1.40-3.15, p<0.001), 9N (RRR 2.21, 95% CI 1.21-4.04, p=0.009), 7F ( 
RRR 2.14, 95% CI 1.14-4.06, p=0.019), 25 (RRR 2.63, 95% CI 1.32-5.28 p=0.006) 
and 5 (RRR 6.31, 95% CI 2.21-18.04, p=0.001) were more likely to cause 
bacteremia (Figure 6). In addition, serotypes 1 (RRR 1.51, 95% CI 1.12-2.04 
p=0.007), 23F (RRR 1.61, 95% CI 1.12-2.30, p=0.010) and 19F (RRR 2.32, 95% 
CI 1.60-3.37, p<0.001) were significantly more likely to cause death in patients 
compared to serotype 4. Serotype 25 (RRR 0.44, 95% CI 0.22-0.91, p=0.027) was 
significantly less likely to cause death in patients compared to serotype 4 (Figure 
7). 
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Figure 4: Distribution of IPD serotypes by age groups, GERMS-SA, 2003 to 2008.   
# Referent group. * Significant serotypes.                    
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Figure 5: Distribution of IPD serotypes by HIV status, GERMS-SA, 2003 to 2008. 
 # Referent group. * Significant serotypes.                    
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Figure 6: Distribution of IPD serotypes by clinical diagnosis, GERMS-SA, 2003 to 2008.          
# Referent group. * Significant serotypes.                    
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 Figure 7: Distribution of IPD serotypes by in-hospital outcome, GERMS-SA, 2003 to 2008.   
# Referent group. * Significant serotypes.                    
 
 
 
44 
 
3.5 Comparison of cases presenting to enhanced and non-enhanced sites 
 
Of the total number of cases 7610/16459 (46%) were from enhanced sites while 
8849/16459 (54%) were from non-enhanced sites. On univariate analysis, there 
were significantly less cases reported from the provinces with intermediate poverty 
rates (OR 0.78, 95% CI 0.72-0.84) and high poverty rates (OR 0.27, 95% CI 0.23-
0.30), compared to those with low poverty rates at enhanced sites. Patients 
belonging to White, Colored and Indian race groups were more likely to present at 
enhanced sites compared to non-enhanced sites (OR 4.21, 95% CI 3.37-5.24). 
 
There was a significant difference in the type of specimen collected between 
enhanced and non-enhanced sites. Positive blood specimens were more likely to 
be collected from enhanced sites (OR 3.15, 95% CI 2.94-3.38) compared to non-
enhanced sites. There were more positive CSF specimens collected at non-
enhanced sites [3949/8849 (45%)], compared to enhanced sites [1817/7610 
(24%)]. Serotypes 19A (OR 1.27, 95% CI 1.16-1.70), 3 (OR 1.31, 95% CI 1.16-
1.79), 9N (OR 1.49, 95% CI 1.18-2.27), 25 (OR 1.53, 95% CI 1.15-2.46) and 22F 
(OR 27.65, 95% CI 9.16-97.49) were more likely to be isolated from patients 
presenting at enhanced sites compared to non-enhanced sites (Table 1).
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Table 1: Comparison of descriptive demographics and clinical factors for adult patients from GERMS-SA enhanced and non-enhanced 
sites (2003-2008). 
 
Variable  Enhanced sites  
N= 7610  
Non-enhanced sites 
N= 8849 
   
  n (%) n (%) Unadjusted OR p 95% CI 
Age group  15-24 years  776/7329 (11) 881/7776 (11) Ref Ref Ref 
 25-44 years 4715/7329 (64) 4889/7776 (63) 1.09 0.089  0.99-1.22 
 45-64 years 1483/7329  (20) 1633/7776 (21) 1.03 0.616 0.91-1.16 
 ≥65 years 355/7329 (5) 373/7776 (5) 1.08 0.384 0.91-1.29 
 Missing 281 1073    
Gender  Females 4013/7540 (53) 4500/8575 (52) Ref Ref Ref 
 Males 3527/7540 (47) 4075/8575 (48) 0.97 0.345 0.91-1.03 
 Missing 70 274    
Province Low poverty 
 
5534/7610 (73) 5144/8849 (58) Ref Ref Ref 
 Intermediate 1521/7610 (20) 1814/8849 (21) 0.78 <0.001 0.72-0.84 
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poverty 
 High poverty 555/7610 (7) 1891/8849 (21) 0.27 <0.001 0.25-0.30 
Race Black 
 
6402/6946 (92) 
 
4751/4847 (98) 
 
Ref 
 
Ref 
 
Ref 
 Other 544/6946 (8) 96/4847 (2) 4.21 <0.001 3.37-5.24 
 Missing 664 4002    
Specimen CSF 1817/7610 (24) 3949/8849 (45) Ref Ref Ref 
 Blood 5116/7610 (67) 3531/8849 (40) 3.15 <0.001 2.94-3.38 
 Other 677/7610 (9) 1369/8849 (15) 1.07 0.189 0.44-0.49 
Serotype 1 775/4651 (17) 
 
1038/5042 (21) 
 
1.10 
 
0.374 
 
0.89-1.36 
 
 19A 498/4651 (11) 
 
438/5042 (9) 
 
1.27 
 
0.019 
 
1.16-1.70 
 4 328/4651 (7) 
 
405/5042 (8) 
 
Ref Ref Ref 
 3 325/4651 (7) 
 
279/5042 (6) 
 
1.31 
 
0.019 
 
1.16-1.79 
 6A 317/4651 (7) 
 
368/5042 (7) 0.97 
 
0.751 
 
0.86-1.31 
 14 298/4651 (6) 
 
334/5042 (7) 
 
1.10 0.374 0.89-1.36 
 23F 312/4651 (7) 338/5042 (7) 1.03 0.761 0.92-1.41 
47 
 
    
 8 234/4651 (5) 261/5042 ( 5) 
 
1.00 
 
0.968 
 
0.88-1.39 
 19F 248/4651 (5) 
 
245/5042 (5) 
 
1.13 
 
0.294 
 
0.99-1.57 
 6B 242/4651 (5) 
 
290/5042 (6) 
 
0.94 
 
0.571 
 
0.82-1.29 
 12F 223/4651 (5) 
 
291/5042 (6) 
 
0.86 
 
0.203 
 
0.75-1.19 
 9V 167/4651 (4) 
 
178/5042 (4) 
 
1.05 
 
0.708 
 
0.90-1.50 
 16 121/4651 (3) 
 
125/5042 (2) 
 
1.08 
 
0.588 
 
0.90-1.60 
 9N 102/4651 (2) 
 
77/5042 (2) 
 
1.49 
 
0.021 
 
1.18-2.27 
 7F 84/4651 (2) 73/5042 (1) 
 
0.89 
 
0.152 1.01-2.01 
 18C 83/4651 (2) 
 
102/5042 (2) 
 
0.91 
 
0.583 
 
0.73-1.39 
 25 75/4651 (2) 
 
55/5042 (1) 
 
1.53 
 
0.029 
 
1.15-2.46 
 22F 74/4651 (2) 
 
3/5042 (0.1) 
 
27.65 
 
<0.001 
 
9.16-97.49 
 13 79/4651 (2) 
 
69/5042 (1) 
 
1.28 
 
0.173 
 
0.99-2.01 
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 5 66/4651 (1) 
 
73/5042 (1) 
 
1.01 
 
0.944 
 
0.78-1.61 
Factors statistically significant on univariate logistic regression presented in boldface.
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3.6 Common serotypes 
Serotype 1 was the most common serotype (651/3953, 16%), followed by serotype 
19A (443/3953, 11%), serotype 4 (289/3953, 7%) serotype 3 (284/3953, 7%) and 
serotype 6A (269/3953, 7%).  
 
3.7 Case-fatality ratios 
The CFR for meningitis was 55% (641/1166) and 23% (576/2484) for bacteremia 
(p<0.001). Serotype 19F had the highest CFR of 48% (100/207), followed by 
serotype 23F with 39% (99/252) and serotype 1 with 38% (246/651).  
3.8 Univariate analysis of risk factors associated with mortality in adults with 
IPD  
On univariate analysis the variables found to be significantly associated with 
mortality using logistic regression p<0.1 were age-group, province, disease 
syndrome, disease severity, prior antibiotic use (24 hours), prior antibiotic use (2 
months), appropriate antibiotic treatment, HIV status, nosocomial infection, 
vaccine serotype, multi-drug resistance and serotype (Table 2).  
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3.9 Multivariable analysis of the association with serotypes and mortality 
rates among adults with IPD, adjusting for other risk factors 
On multivariable analysis  factors independently associated with mortality were 
serotypes 1 (OR 1.93, 95% CI 1.05–3.53) and 19F (OR 2.89, 95% CI 1.38–6.06) 
compared to serotype 4; increasing age (25-44 years, OR 1.75, 95% CI 1.03–2.95; 
45-64 years, OR 3.56, 95% CI 2.00–6.35; ≥65 years, OR 5.17, 95% CI 1.89–
14.14; compared to 15-24 years); living in provinces with intermediate (OR 1.65, 
95% CI 1.16–2.35) or high poverty rates (OR 1.72, 95% CI 1.02–2.92) compared 
to provinces with low poverty rates; having meningitis (OR 4.07, 95% CI 2.98–
5.55) compared to bacteremia; prior antibiotic use in the last two months (OR 3.93, 
95% CI 2.50–6.20); inappropriate antibiotic use (OR 2.37, 95% CI 1.74–3.22) and 
positive HIV status (OR 1.69, 95% CI 1.04–2.75) (Table 2). 
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Table 2: Univariate and multivariable analysis of risk factors for mortality amongst adults with IPD.  
 
Risk factors N=3953 
 
All  
 
CFR  Univariable analysis Multivariable analysis 
  n/N (%) n/N (%) Unadjusted OR p 95% CI Adjusted OR p 95% CI 
Age group 15-24 years 406/3953 
(10) 
92/406 (23) Ref Ref Ref Ref Ref Ref 
 25-44 years 2527/3953 
(64) 
793/2527 
(31) 
1.56 <0.001 1.22 – 2.00 1.75 0.037 1.03 – 2.95 
 45-64 years 810/3953 
(21) 
348/810 (43) 2.57 <0.001 1.96 – 3.37 3.56 <0.001 2.00 – 6.35 
 ≥65 years 210/3953 
(5) 
100/210 (48) 3.10 <0.001 2.17 – 4.43 5.17 0.001 1.89 – 14.14 
Gender Females 2146/3952 
(54) 
719/2146 
(34) 
Ref  Ref Ref - - - 
 Males 1806/3952 
(46) 
614/1806 
(34) 
1.02 0.744 0.90 – 1.17 - - - 
Province Low poverty 2934/3953 
(74) 
915/2934 
(31) 
Ref Ref Ref Ref Ref Ref 
 Intermediate poverty 780/3953 (20) 301/780 (39) 1.39 <0.001 1.18 – 1.63 1.65 0.005 1.16 – 2.35 
 High poverty 239/3953 (6) 117/239 (49) 2.12 <0.001 1.62 – 2.76 1.72 0.042 1.02 – 2.92 
Race Black 3534/3930 
(90) 
1203/3534 
(34) 
Ref Ref Ref - - - 
 Other 396/3030 (10) 121/396 (31) 0.85 0.164 0.68 – 1.07 - - - 
Disease syndrome Meningitis 1166/3923 
(30) 
641/1166 
(55) 
4.04 <0.001  1.16 – 2.19 4.07 <0.001 2.98 – 5.55 
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 Bacteremia 2484/3923 
(63) 
576/2484 
(23) 
Ref Ref Ref Ref Ref Ref 
 Other 273/3923 
(7) 
98/273 (36) 1.86 <0.001 0.29 – 0.54 1.61 0.104 0.91 – 2.85 
Disease severity Pitt bacteremia score 
<4 
2933/3953 
(76) 
864/2993 
(29) 
Ref Ref Ref NS NS NS 
 Pitt bacteremia score 
≥4 
429/3953 
(11) 
292/429 (60) 2.35 <0.001 2.03 – 2.73 NS NS NS 
Prior antibiotic use 
(24 hours) 
Yes 96/2968 (3) 41/96 (43) 2.08 0.001 1.37 – 3.14 NS NS NS 
 No 2872/2968 
(97) 
759/2872 
(26) 
Ref Ref Ref NS NS NS 
Prior antibiotic use (2 
months) 
Yes 149/2402 (6) 59/149 (40) 2.57 <0.001 1.82 – 3.62 3.93 <0.001 2.50 – 6.20 
 No 2253/2402 
(94) 
458/2253 
(20) 
Ref Ref Ref Ref Ref Ref 
Appropriate antibiotic 
use 
Yes 3005/3923 
(77) 
900/3005 
(30) 
Ref Ref Ref Ref Ref Ref 
 No 918/3923 (23) 415/918 (45) 1.93 <0.001 1.66 -2.25 2.37 <0.001 1.74 – 3.22 
Underlying medical 
conditions  
Yes 1022/3953 
(26) 
328/1022 
(32) 
0.91 0.201 0.78 – 1.05 - - - 
 No 2931/3953 
(74) 
1005/2931 
(34) 
Ref Ref Ref - - - 
HIV status Positive 2309/2580 
(58) 
687/2309 
(30) 
1.46 0.013 1.08 – 1.97 1.69 0.035 1.04 – 2.75 
 Negative 271/2580 (7) 61/271 (23) Ref Ref Ref Ref Ref Ref 
Nosocomial infection Yes 168/3953 (4) 73/168 (44) 1.54 0.007 1.13 – 2.10 NS NS NS 
 No 3785/3953 1260/3785 Ref Ref Ref NS NS NS 
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(96) (33) 
Penicillin resistance Resistant 1089/3953 
(28) 
385/1089 
(35) 
Ref Ref Ref - - - 
 Susceptible 2864/3953 
(72) 
948/2864 
(33) 
0.90 0.181 0.78 – 1.05 - - - 
Multi-drug resistant Yes 609/3953 (15) 230/609 (38) 1.23 0.022 1.03 – 1.47 NS NS NS 
 No 3344 (85) 1103/3344 
(33) 
Ref Ref Ref NS NS NS 
Serotype 1 651/3953 (17) 246/651 (38) 1.51 0.007 1.12 – 2.04 1.93 0.034 1.05 – 3.53 
 19A 443/3953 (11) 151/443 (34) 1.28 0.128 0.93 – 1.77 1.79 0.075 0.94 – 3.41 
 4 289/3953 (7) 83/289 (29) Ref Ref Ref Ref Ref Ref 
 3 284/3953 (7) 98/284 (35) 1.31 0.137 0.92 – 1.86 1.15 0.727 0.53 – 2.51 
 6A 269/3953 (7) 89/269 (33) 1.23 0.265 0.86 – 1.76 0.78 0.501 0.37 – 1.63 
 14 253/3953 (6) 83/253 (33) 1.21 0.303 0.84 – 1.75 2.05 0.049 1.00 – 4.20 
 23F 252/3953 (6) 99/252 (39) 1.61 0.010 1.12 -  2.30 1.89 0.073 0.94 – 3.80 
 8 209/3953 (5) 52/209 (25) 0.82 0.342 0.55 – 1.23 1.21 0.637 0.54 – 2.72 
 19F 207/3953 (5) 100/207 (48) 2.32 <0.001 1.60 – 3.37 2.89 0.005 1.38 – 6.06 
 6B 202/3953 (5) 64/202 (32) 1.15 0.481 0.78 – 1.70 1.35 0.428 0.65 – 2.80 
 12F 175/3953 (4) 60/175 (34) 1.30 0.209 0.87 – 1.94 1.16 0.757 0.46 – 2.89 
 9V 140/3953 (4) 45/140 (32) 1.18 0.468 0.76 – 1.82 1.81 0.187 0.75 – 4.37 
 16 103/3953 (3) 34/103 (33) 1.22 0.414 0.75 – 1.98 0.44 0.201 0.13 – 1.54 
 9N 89/3953 (2) 26/89 (29) 1.02 0.928 0.61 – 1.73 0.92 0.888 0.28 – 3.01 
 7F 73/3953 (2) 15/73 (21) 0.64 0.163 0.34 – 1.20 0.97 0.965 0.32 – 2.99 
 18C 68/3953 (2) 24/68 (35) 1.35 0.288 0.77 – 2.37 1.33 0.611 0.44 – 4.07 
 25 66/3953 (2) 10/66 (15) 0.44 0.027 0.22 – 0.91 0.76 0.701 0.19 – 3.06 
 22F 64/3953 (2) 22/64 (34) 1.30 0.371 0.73 – 2.31 1.31 0.674 0.37 – 4.62 
 13 63/3953 (2) 21/63 (33) 1.24 0.468 0.69 – 2.22 1.95 0.234 0.65 – 5.83 
 5 53/3953 (1) 11/53 (21) 0.65 0.235 0.32 – 1.32 0.28 0.291 0.03 – 2.98 
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Factors statistically significant on multivariable logisitic regression presented in boldface. 
- Factors not statistically significant on univariate logistic regression (p>0.1) were omitted from the multivariable logistic regression model (except for 
the serotype-specific comparison). 
NS: Factors not statistically significant on multivariable logistic regression (p≥0.05) (except for the serotype-specific comparison).
Vaccine serotype Yes 3254/3953 
(82) 
1116/3254 
(34) 
1.16 0.099 0.97 – 1.38 - - - 
 No 669 /3953 
(18) 
217/699 (31) Ref Ref Ref - - - 
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3.10. Multivariable analysis of the association with serotypes and mortality 
rates among adults with IPD amongst disease syndromes, adjusting for 
other risk factors.  
On multivariable analysis restricted to patients presenting with bacteremic 
pneumonia, the factors independently associated with mortality were serotypes 14 
(OR 2.20, 95% CI 1.04-4.67) and 19F (OR 3.54, 95% CI 1.58-7.96) compared to 
serotype 4; increasing age (25-44 years, OR 2.94, 95% CI 1.32-6.56; 45-64 years 
OR 6.95, 95% CI 3.05-15.88; ≥65 years OR 13.05. 95% CI 5.29-32.19 compared 
to 15-24 years); prior antibiotic use in the last two months (OR 2.32, 95% CI 1.39-
3.87) and inappropriate antibiotic treatment (OR 2.75, 95% CI 1.97-3.83) (Table 
3). 
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Table 3: Univariate and multivariable analysis of risk factors for mortality amongst adults with bacteremic pneumonia.  
 
Risk factors N=2514 
 
All  
 
CFR  Univariable analysis Multivariable analysis 
  n/N (%)  Unadjusted OR p  95% CI Adjusted OR p  95% CI 
Age group 15-24 years 227/2514 (9) 25/227 (11) Ref Ref Ref Ref Ref Ref 
 25-44 years 1601/2514 
(64) 
329/1601 (21) 2.09 0.001 1.36-3.22  2.94 0.009 1.32-6.56 
 45-64 years   533/2514 (21) 179/533 (34) 4.09  <0.001 2.60-6.43 6.95 <0.001 3.05-15.88 
 ≥65 years 153/2514 (6) 61/153 (40) 5.36 <0.001 3.16-9.07 13.05 <0.001 5.29-32.19 
Gender Females 1319/2513 
(52) 
296/1319 (22) Ref Ref Ref Ref Ref Ref 
 Males 1194/2513 
(48) 
298/1194 (25) 1.15 0.138 0.96-1.38 - - - 
Province Low poverty 2020/2514 
(80) 
455/2020 (23) Ref Ref Ref Ref Ref Ref 
 Intermediate poverty 432/2514 (17) 123/432 (29) 1.37 0.008 1.08-1.73 NS NS NS 
 High poverty 62/2514 (3) 16/62 (26) 1.20 0.543 0.67-2.13 - - - 
Race Black 2213/2499 
(89) 
519/2213 (24) Ref Ref Ref Ref Ref Ref 
 Other 286 (11) 70/286 (25) 1.06 0.701 0.79-1.41 - - - 
Disease severity Pitt bacteremia 
score <4 
1984/2514 
(79) 
406/1984 (21) Ref Ref Ref Ref Ref Ref 
 Pitt bacteremia 530/2514 (21) 188/530 (36) 2.14 <0.001 1.73-2.63 NS NS NS 
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score ≥4 
Prior antibiotic use (24 
hours) 
Yes 41/1956 (2) 15/41 (37) 2.75 0.002 1.44-5.25 NS NS NS 
 No 1915/1956 
(98) 
332/1915 (17) Ref Ref Ref Ref Ref Ref 
Prior antibiotic use (2 
months) 
Yes 97/1633 (6) 29/97 (30) 2.72 <0.001 1.72-4.31 2.32 0.001 1.39-3.87 
 No 1536/1633 
(94) 
208/1536 (14) Ref Ref Ref Ref Ref Ref 
Appropriate antibiotic use Yes 1976/2484 
(80) 
397/1976 (20) Ref Ref Ref Ref Ref Ref 
 No 508/2484 (20) 179/508 (35) 2.16 <0.001 1.75-2.68 2.75 <0.001 1.97-3.83 
Underlying medical 
conditions  
Yes 706/2514 (28) 183/706 (26) 1.19 0.091 0.97-1.45 - - - 
 No 1808/2514 
(72) 
411/1808 (23) Ref Ref Ref Ref Ref Ref 
HIV status Positive 1562/1733 
(90) 
322/1562 (21) 1.01 0.964 0.68-1.49 - - - 
 Negative 171/1733 (10) 35/171 (21) Ref Ref Ref Ref Ref Ref 
Nosocomial infection Yes 89/2514 (4) 32/89 (36) 1.86 0.006 1.19-2.90 NS NS NS 
 No 2425/2514 
(96) 
562/2425 (23) Ref Ref Ref Ref Ref Ref 
Penicillin resistance Yes 696/2514 (28) 192/696 (28) 1.34 0.004 1.10-1.64 NS NS NS 
 No 1818/2514 
(72) 
402/1818 (22) Ref Ref Ref Ref Ref Ref 
Multi-drug resistance Yes 375/2514 (15) 111/375 (30) 1.44 0.003 1.13-1.84 NS NS NS 
 No 2139/2514 
(85) 
483/2139 (23) Ref Ref Ref Ref Ref Ref 
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Serotype 1 365/2514 (15) 62/365 (17) 1.02 0.947 0.63-1.64  1.15 0.709 0.55-2.38 
 19A 344/2514 (14) 94/344 (27) 1.87 0.008 1.18-2.95 1.52 0.251 0.75-3.05 
 4 179/2514 (7) 30/179 (17) Ref Ref Ref Ref Ref Ref 
 3 223/2514 (9) 73/223 (33) 2.42 <0.001 1.49-3.91 2.01 0.061 0.97-4.20 
 6A 139/2514 (6) 32/139 (23) 1.49 0.164 0.85-2.59 0.72 0.517 0.27-1.95 
 14 188/2514 (7) 58/188 (31) 2.22 0.002 1.34-3.65 2.20 0.039 1.04-4.67 
 23F 125/2514 (5) 27/125 (22) 1.37 0.288 0.77-2.44 1.52 0.352 0.63-3.65 
 8 139/2514 (6) 15/139 (11) 0.60 0.133 0.31-1.17 0.81 0.649 0.32-2.04 
 19F 116/2514 (5) 51/116 (44) 3.90 <0.001 2.28-6.67 3.54 0.002 1.58-7.96 
 6B 125/2514 (5) 23/125 (18) 1.12 0.711 0.62-2.04 0.97 0.954 0.38-2.46 
 12F 80/2514 (3) 16/80 (20) 1.24 0.529 0.63-2.04 1.16 0.778 0.41-3.34 
 9V 98/2514 (4) 25/98 (26) 1.70 0.083 0.93-3.10 2.01 0.153 0.77-5.21 
 16 69/2514 (3) 20/69 (29) 2.03 0.033 1.06-3.89 0.63 0.508 0.16-2.44 
 9N 66/2514 (3) 17/66 (26) 1.72 0.115 0.88-3.39 1.11 0.863 0.35-3.53 
 7F 56/2514 (2) 10/56 (18) 1.08 0.849 0.49-2.38 0.89 0.868 0.23-3.45 
 18C 27/2514 (1) 7/27 (26) 1.74 0.252 0.68-4.48 1.47 0.583 0.37-5.83 
 25 54/2514 (2) 7/54 (13) 0.74 0.505 0.31-1.79 0.54 0.440 0.11-2.60 
 22F 43/2514 (2) 11/43 (26) 1.71 0.184 0.78-3.76 1.55 0.498 0.43-5.56 
 13 31/2514 (1) 7/31 (23) 1.45 0.434 0.57-3.67 1.64 0.435 0.47-5.68 
 5 47/2514 (2) 9/47 (19) 1.18 0.700 0.52-2.69 0.73 0.703 0.15-3.58 
Vaccine serotype Yes 2068/2514 
(82) 
494/2068 (24) 1.09 0.509 0.85-1.39 - - - 
 No 446/2514 (18) 100/446 (22) Ref Ref Ref - - - 
Factors statistically significant on multivariable logisitic regression presented in boldface. 
- Factors not statistically significant on univariate logistic regression (p>0.1) were omitted from the multivariable logistic regression model (except for 
the serotype-specific comparison). 
NS: Factors not statistically significant on multivariable logistic regression (p≥0.05) (except for the serotype-specific comparison).
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On multivariable analysis restricted to patients presenting with meningitis, the 
factors independently associated with mortality were ages 45-64 years (OR 6.32, 
95% CI 2.53-15.80) compared to 15-24 years; disease severity (OR 2.55, 95% CI 
1.51-4.31); prior antibiotic use in the last two months (OR 5.05, 95% CI 2.04-
12.53); positive HIV status (OR 4.86, 95% CI 1.83-12.91) and vaccine serotypes 
(OR 1.39, 95% CI 1.03-1.97). Individual serotypes were not statistically 
significantly associated with mortality but were included in the multivariable 
analysis as it is the predictor/exposure variable and was selected a priori (Table 
4).  
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Table 4: Univariate and multivariable analysis of risk factors for mortality amongst adults with meningitis.  
 
Risk factors N=1196 
 
All  
 
CFR  Univariable analysis Multivariable analysis 
  n/N (%)  Unadjusted OR p  95% CI Adjusted OR p  95% CI 
Age group 15-24 years 143/1196 (12) 56/143 (39) Ref Ref Ref Ref Ref Ref 
 25-44 years 789/1196 (66) 430/789 (55) 1.86 0.001 1.29-2.68 1.80 0.125 0.85-3.83 
 45-64 years   232/1196 (19) 149/232 (64) 2.79 <0.001 1.81-4.29 6.32 <0.001 2.53-15.80 
 ≥65 years 32/1196 (3) 24/32 (75) 4.66 0.001 1.96-
11.10 
5.91 0.168 0.47-74.18 
Gender Females 693/1196 (58) 379/693 (55) Ref Ref Ref Ref Ref Ref 
 Males 503/1196 (42) 280/503 (56) 1.04 0.738 0.83-1.31 - - - 
Province Low poverty 730/1196 (61) 388/730 (53) Ref Ref Ref Ref Ref Ref 
 Intermediate poverty 298/1196 (25) 174/298 (58) 1.24 0.126 0.94-1.62 - - - 
 High poverty 168/1196 (14) 97/168 (58) 1.20 0.282 0.86-1.69 - - - 
Race Black 1125/1190 
(95) 
631/1125 
(56) 
Ref Ref Ref Ref Ref Ref 
 Other 65/1190 (5) 25/65 (39) 0.49 0.006 0.29-0.82 NS NS NS 
Disease severity Pitt bacteremia score 
<4 
822/1196 (69) 408/822 (50) Ref Ref Ref Ref Ref Ref 
 Pitt bacteremia score 
≥4 
374/1196 (31) 251/374 (67) 2.07 <0.001 1.60-2.67 2.55 <0.001 1.51-4.31 
Prior antibiotic use (24 
hours) 
Yes 45/830 (5) 24/45 (53) 1.26 0.458 0.69-2.29 - - - 
 No 785/830 (95) 374/785 (48) Ref Ref Ref Ref Ref Ref 
Prior antibiotic use (2 Yes 36/630 (6) 24/36 (67) 3.21 0.001 1.57-6.55 5.05 <0.001 2.04-12.53 
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months) 
 No 594/630 (94) 228/594 (38) Ref Ref Ref Ref Ref Ref 
Appropriate antibiotic use Yes 832/1166 (71) 439/832 (53) Ref Ref Ref Ref Ref Ref 
 No 334/1166 (29) 202/334 (61) 0.73 0.017 0.56-0.94 NS NS NS 
Underlying medical 
conditions  
Yes 215/1196 (18) 95/215 (44) 0.56 <0.001 0.43-0.79 NS NS NS 
 No 981/1196 (82) 564/981 (58) Ref Ref Ref Ref Ref Ref 
HIV status Positive 646/720 (90) 341/646 (53) 3.02 <0.001 1.77-5.16 4.86 0.002 1.83-12.91 
 Negative 74/720 (10) 20/74 (27) Ref Ref Ref Ref Ref Ref 
Nosocomial infection Yes 44/1196 (4) 24/44 (55) 0.98 0.940 0.54-1.79 - - - 
 No 1152/1196 
(96) 
635/1152 
(55) 
Ref Ref Ref Ref Ref Ref 
Penicillin resistance Yes 320/1196 (27) 168/320 (53) Ref Ref Ref Ref Ref Ref 
 No 876/1196 (73) 491/876 (56) 1.15 0.275 0.89-1.49 - - - 
Multi-drug resistance Yes 181/1196 (15) 100/181 (55) 1.01 0.965 0.73-1.38 - - - 
 No 1015/1196 
(85) 
559/1015 
(55) 
Ref Ref Ref Ref Ref Ref 
Serotype 1 245/1196 (20) 176/245 (72) 2.21 0.001 1.36-3.59 1.85 0.149 0.80-4.25 
 19A 84/1196 (7) 53/84 (63) 1.48 0.198 0.81-2.69 1.13 0.811 0.41-3.18 
 4 97/1196 (8) 52/97 (54) Ref Ref Ref Ref Ref Ref 
 3 42/1196 (4) 17/42 (41) 0.59 0.157 0.28-1.23 0.16 0.103 0.02-1.45 
 6A 110/1196 (9) 51/110 (46) 0.75 0.299 0.43-1.29 0.46 0.125 0.17-1.24 
 14 51/1196 (4) 23/51 (45) 0.71 0.326 0.36-1.40 0.46 0.267 0.11-1.83 
 23F 107/1196 (9) 59/107 (55) 1.06 0.826 0.61-1.85 0.86 0.765 0.33-2.28 
 8 59/1196 (5) 33/59 (56) 1.10 0.777 0.57-2.11 0.89 0.851 0.26-3.01 
 19F 64/1196 (5) 35/64 (55) 1.04 0.893 0.55-1.97 0.69 0.567 0.19-2.49 
 6B 69/1196 (6) 39/69 (57) 1.13 0.710 0.60-2.09 1.02 0.975 0.35-2.96 
 12F 76/1196 (6) 38/76 (50) 0.87 0.637 0.47-1.58 0.71 0.598 0.20-2.56 
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 9V 41/1196 (3) 21/41 (51) 0.91 0.797 0.44-1.89 0.14 0.098 0.01-1.44 
 16 31/1196 (3) 13/31 (42) 0.63 0.260 0.28-1.42 0.26 0.073 0.06-1.13 
 9N 16/1196 (3) 6/16 (38) 0.52 0.238 0.17-1.54 0.41 0.444 0.04-4.03 
 7F 14/1196 (1) 3/14 (21) 0.24 0.034 0.06-0.90 0.38 0.271 0.07-2.12 
 18C 31/1196 (3) 15/31 (48) 0.81 0.613 0.36-1.82 1.36 0.716 0.26-7.00 
 25 11/1196 (1) 3/11 (27) 0.32 0.111 0.08-1.30 0.16 0.155 0.01-2.01 
 22F 17/1196  (1) 9/17 (53) 0.97 0.959 0.35-2.73 0.45 0.409 0.07-3.01 
 13 27/1196 (2) 11/27 (41) 0.59 0.239 0.25-1.41 1.15 0.851 0.26-5.17 
 5 4/1196 (0) 2/4 (50) 0.87 0.887 0.12-6.40 0.83 0.923 0.02-36.02 
Vaccine serotype Yes 981/1196 (82) 555/981 (57) 1.39 0.029 1.03-1.87 1.39 0.029 1.03-1.87 
 No 215/1196 (18) 104/215 (48) Ref Ref Ref Ref Ref Ref 
Factors statistically significant on multivariable logisitic regression presented in boldface. 
- Factors not statistically significant on univariate logistic regression (p>0.1) were omitted from the multivariable logistic regression model (except for 
the serotype-specific comparison). 
NS: Factors not statistically significant on multivariable logistic regression (p≥0.05) (except for the serotype-specific comparison).
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CHAPTER 4 
Discussion 
4.1 Overview of study findings 
 
This study done in the pre-vaccine era, serves as an important baseline from 
which to monitor the effects of PCV. Serotype 1 was the most common serotype 
followed by serotype 19A, serotype 4, serotype 3 and serotype 6A. The incidence 
of serotypes 4, 19A, 23F and 18C increased significantly while the incidence of 
serotype 1, 25 and 5 decreased significantly from 2003 to 2008. Serotype 19F had 
the highest CFR, followed by serotype 23F and serotype 1. This serotype 
distribution data could potentially help policy makers when deciding on introducing 
or transitioning to newer vaccines. S pneumoniae showed seasonal patterns with 
the peak incidences of IPD in the winter months (May to August). There was no 
evidence of obvious outbreaks during the study period. Increased crowding, 
temperature, humidity, light intensity and pollution have been suggested to cause 
annual fluctuations in IPD incidence (98-100). 
 
On multivariable analysis, factors independently associated with mortality were 
disease caused by serotypes 1 and 19F compared to serotype 4, increasing age, 
living in provinces with intermediate or high poverty rates, having meningitis, prior 
antibiotic treatment in the last two months, inappropriate antibiotic treatment and 
positive HIV status. Serotypes associated with increased mortality are included in 
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the 10-and-13-valent pneumococcal conjugate vaccine and may be expected to 
become less common in adults as a result of indirect effects following routine 
immunization in infants. HIV-infected adults experience increased mortality which 
may be reduced by more widespread availability of antiretroviral therapy which will 
in turn substantially improve the quality of life of HIV-infected individuals in terms 
of physical and mental health and decrease the incidence of IPD and therefore 
mortality. 
 
4.1.1 Serotypes associated with mortality 
 
On multivariable analysis, serotypes 1 and 19F compared to serotype 4 were 
independently associated with mortality. Consistent with our findings, previous 
studies also found 19F to be associated with increased CFRs (57;58;101). Our 
findings also corroborates studies performed by Martens et al (63) which showed 
that serotype 1 was independently associated with mortality after controlling for 
age and other markers of disease severity. However, in contrast to our study, 
Weinberger et al (57) and Jansen et al (58) showed that serotype 1 was 
associated with the decreased risk of death. A possible explanation for this could 
be that the high prevalence of serotype 1 in our setting resulted in a substantial 
increase in power to detect a significant association of serotype 1 with mortality.  
 
Moreover in previous studies, serotype 1 was found to be among the more 
invasive serotypes and serotype 19F was found to be among the less invasive 
serotypes (2;58;65;101). Previous studies also showed that serotypes with 
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increased RRs of death had a higher carriage prevalence and low invasiveness 
(57). Differences in our findings compared to other studies could be due to 
different populations being studied at different time points. Our decision to use 
serotype 4 as the referent group may also account for differences in our findings 
compared to other studies.  
 
Consistent with previous studies, serotype 1 was found to be the commonest 
serotype in our study (5;60;101). Serotype 1 was also found to cause large 
outbreaks of IPD in the pre-antibiotic era (24). It has more recently been the cause 
of outbreaks of meningitis in Western Africa (102). However, there is no evidence 
of serotype 1 outbreaks in our population.  
 
These findings may be useful to similar countries with similar populations who lack 
surveillance programs. Previous studies have shown that vaccination of young 
children with PCV-7 and PCV-13 inhibits nasopharyngeal carriage of vaccine 
serotypes and have the potential of also having indirect effects among older, 
unvaccinated individuals (103-106). Thus, serotypes 1 and 19F may be expected 
to become less common in adults as a result of indirect effects following routine 
immunization in infants. A potential concern is that replacement invasive disease 
caused by non-vaccine serotypes may occur after vaccination introduction, as 
seen in previous studies (101;107-109) and this may result in implications for 
immunocompromised individuals, particularly HIV-infected individuals with regard 
to disease severity and mortality (110). Continuous surveillance is required to 
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monitor IPD caused by non-vaccine serotypes to ensure that future vaccines 
include the relevant serotypes that are associated with mortality.  
 
On multivariable analysis restricted to patients presenting with bacteremic 
pneumonia, serotypes 14 and 19F compared to serotype 4 were significantly 
associated with mortality. When restricted to meningitis, no individual serotypes 
were significantly associated with mortality. This is consistent with findings from 
the study performed by Weinberger et al (57) where in patients with bacteremic 
pneumonia caused by serotypes 3, 6A, 6B, 9N and 19F compared to serotype 14 
were significantly more likely to die. 
 
 It was also found that among patients with meningitis, there were no individual 
serotypes that were significantly associated with mortality, compared to serotype 
14. A possible explanation for the disjunction between serotypes associated with 
mortality in patients with bacteremic pneumonia and meningitis could be due to the 
high mortality rates in patients with meningitis, difficultly in diagnosing meningitis, 
and the fact that meningitis is a serious condition and serotypes may have a 
different and less important role in this instance. 
 
4.1.2 Age as a risk factor for mortality 
 
Using age-group 15-24 years as the referent group, increasing age remained 
significantly associated with mortality in our study. This corroborates several other 
studies (74;75;111). This could be due to the fact that as individuals age, their 
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immune systems age as well, a phenomenon known as immunosenescence. This 
makes older individuals more susceptible to have more severe disease and poor 
outcomes (112). 
 
4.1.3 HIV as a risk factor for mortality 
 
The proportion of IPD cases who were HIV co-infected was high (89%) and more 
prevalent in the 25-44 year age-group (73%). A minimal proportion of HIV-infected 
patients were on ART (8%). In addition, the CFR for HIV-infected individuals was 
high (30%). The high proportion of HIV co-infection and CFR are consistent with 
other studies where despite large reductions in IPD among HIV-infected adults 
following PCV-7 and HAART introduction, IPD still causes substantial morbidity 
and mortality among HIV-infected individuals in whom the burden of HIV and IPD 
was high (80-82). 
 
In this study HIV-infected patients were 1.69 times more likely to die compared to 
HIV-uninfected patients. This association has not been seen in other studies. 
Frankel et al (113) reviewed 147 episodes of IPD patients hospitalized with and 
without HIV. Results showed that the overall mortality rate was 12% and did not 
vary by HIV status (HIV-infected, 13%, HIV-uninfected 12%). In addition, several 
other studies compared mortality between HIV-infected (9%-21%) and HIV-
uninfected (3%-15%) patients found no significant differences in mortality between 
the two populations (114-116). A possible explanation for the statistically 
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significant association between HIV infection and mortality that is seen in our study 
and not other studies could be that the high prevalence of HIV-infected individuals 
(89%) in our study population enabled us to detect a significant association of HIV 
co-infection with mortality. The CFR (30%) in our study is higher than the CFRs 
reported in previous studies (113;116). Details on staging of HIV infection was not 
collected. However, of the HIV-infected individuals, 51% (1184/2309) had CD4+ 
counts of <200 cells/µL. Therefore, the high CFRs could be due to late 
presentation of patients to the hospitals, patients presenting with advanced stages 
of HIV at the time of presentation to the hospital as well as delays in patient 
admission due to a stressed health care system.   
 
Our findings also show that positive HIV status was independently associated with 
mortality in patients presenting with meningitis. This is consistent with findings 
from a previous South African study by Nunes et al (82) where HIV-infected 
meningitis patients had a higher CFR (55.2%) compared to non-meningitis 
patients (22.4%, p<0.0001). Another South African study by Nyasulu et al (73) 
showed that in HIV-infected individuals with meningitis were 5.34 times to die 
when compared to HIV-uninfected individuals (OR 5.34, 95% CI 2.32-12.29).  
 
This study highlights that HIV-infected patients have a higher risk of mortality 
resulting from IPD. It is believed that the widespread availability of antiretroviral 
therapy will substantially improve the quality of life of HIV-infected individuals in 
terms of physical and mental health and decrease the incidence of IPD and 
therefore mortality (8). The combined effects of childhood vaccination and access 
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to ART could also reduce the burden of IPD (110;117). Nunes et al (59) showed 
that in HIV-infected adults vaccination with PCV induces more functional and 
durable antibody responses in individuals on ART as opposed to individuals not on 
ART at the time of vaccination.  
 
4.1.4 Meningitis as a risk factor for mortality 
 
Pneumococcal meningitis was significantly associated with mortality compared to 
bacteremia. The CFR for meningitis was 55% (641/1166). This is in accordance 
with previous findings from a Malawian study where the inpatient mortality rate 
was 65%, 20% and 26% for meningitis, pneumonia and bacteremia respectively 
and a significant difference in inpatient mortality between patients with meningitis 
(OR 7.5, 95% CI 3.6-15.5) and bacteremia (OR 5.3, 95% CI 2.3-12.5) compared to 
patients with pneumonia was seen (118). Harboe et al (101) also demonstrated 
that in patients >5 years of age, meningitis was independently associated with 30-
day mortality compared to bacteremia (OR 2.05 95% CI 1.02-4.09).  
 
4.1.5 Provinces as a risk factor for mortality 
 
When compared to provinces with low poverty rates, provinces with intermediate 
and high poverty rates remained independently associated with mortality. This has 
been seen in other studies where mortality rates were much higher in young 
children in developing countries (10-40%) compared to developed countries, 
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possibly due to poorer access to health care (101). A more recent population-
based study assessing the relationship between IPD and socioeconomic 
deprivation in North East England showed that the incidence of IPD increased 
linearly with increasing socioeconomic deprivation from 7.0 per 100 000 population 
to 13.6 per 100 000 population in the 16-64 age-group. A possible explanation for 
our findings could be due to the differences in the availability of and access to 
health care services. This could result in differential outcome in patients presenting 
with IPD. In addition, specimens are only taken from very ill patients in less 
resourced provinces thus difference in specimen-taking practices could lead to the 
difference in the spectrum of patients between provinces. These findings reinforce 
the urgency to address social inequalities in order to reduce the burden of IPD 
(119).  
 
4.1.6 Prior antibiotic use within 2 months before admission as a risk factor 
for mortality 
 
Results of this study show that prior antibiotic use within two months of admission 
was significantly associated with mortality. Previous studies have utilized data on 
prior antibiotic use before the patient’s admission as a marker for possible 
antibiotic resistance (9;120). However, our study did not find a significant 
association between penicillin resistance and mortality or between multi-drug 
resistance and mortality. A most likely explanation for the statistically significant 
association found between prior antibiotic use in the past two months and mortality 
could be that these patients had underlying medical illnesses which often resulted 
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in them accessing heath care facilities for treatment. Results from a Danish study 
showed that patients with underlying medical illnesses that required frequent 
hospitalizations were also at increased risk of being admitted for IPD (aRR: 1.4, 
95% CI: 1.1–1.8) (121).  
 
4.1.7 Inappropriate antibiotic treatment associated with mortality 
 
This study shows that inappropriate antibiotic treatment was associated with 
mortality. This suggests that patients who were not administered the appropriate 
drug were 2.37 times more likely to die compared to those who were administered 
the appropriate treatment. This is in accordance with studies by Yu et al (9) which 
showed that discordant therapy (receipt of a single antibiotic within the first two 
days of blood collection that was intermediately resistant or resistant in vitro 
against S.pneumoniae) with cefuroxime had a higher mortality rate compared to 
patients treated with concordant therapy (36.4% [n=4], p=0.02). Our findings are 
also consistent with findings from a study conducted in Barcelona, Spain to 
determine the risk factors for mortality in patients with community-acquired 
pneumonia. It was found that discordant antibiotic treatment was significantly 
associated with mortality (OR 11.28, 95% CI 3.50-36.39) (122). This could be due 
to the fact that discordant antibiotic therapy could result in failed treatment which in 
turn could result in an increased risk of mortality. In South Africa, the sale of 
antibiotics is under control. However, it is imperative that physicians in the public 
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and private sectors are aware of S.pneumoniae resistance and the effective 
antibiotics to be used in their region.  
 
4.1.8 Factors not associated with mortality 
 
Disease severity (Pitt bacteremia score ≥4) was not found to be associated with 
mortality. This is contrary to previous studies (8;87;123). This could be due to 
some limitations in our study, as with all surveillance systems, where detailed data 
on clinical indicators if disease severity including mechanical ventilation, Glasgow 
coma score, and other parameters such as white blood cell count were 
incomplete. Therefore, an in-depth analysis of clinical risk factors associated with 
mortality could not be assessed.  
 
However, when restricted to meningitis patients, our results found a significant 
association between disease severity (Pitt bacteremia score ≥4) and an increased 
risk of dying (OR 4.86, 95% CI 1.83-12.91). A possible reason for this is that 
meningitis is associated with fever, decreased levels of consciousness and the 
need for mechanical ventilation. The above mentioned parameters are used to 
calculate the Pitt bacteremia score. This corroborates other findings as meningitis 
occurs relatively infrequently and is associated with severe disease resulting in 
high mortality in adults (CFR=30%, N=352) (124). Previous studies also show that 
the presence of severe illness that was assessed using the Pitt bacteremia score, 
was significantly associated with mortality in patients with meningitis and other IPD 
and may be a representation of overwhelming systemic disease with an inevitable 
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adverse outcome (6;8;9;125;126). The Glasgow coma scale (GCS) is an objective 
measurement that is usually used to assess a patient’s level of consciousness 
(127). We tried to collect information on GCS but unfortunately the data collected 
was incomplete, which is a potential limitation.  
 
Additionally, underlying medical conditions was found not to be associated with 
mortality. This is inconsistent with other studies (76;77). However, this is could be 
due to limitations in our study where data on underlying medical conditions may 
not have been filled out completely or uniformly. Differences in our findings could 
also be due to the differences in population structure with developed countries 
having a higher prevalence of underlying medical conditions than developing 
countries. In contrast to previous studies (76;77) , our underlying medical 
conditions variable excluded HIV status which was analysed separately and as 
previously mentioned, HIV-infected patients comprised 89% of our study 
population.  
 
Penicillin and multi-drug resistance was also found not to be associated with 
mortality. The most likely explanation for this finding is that our analysis included 
patients with invasive disease that required hospitalization. Most of these patients 
would have been treated with high doses of penicillin and this would have been 
adequate treatment as the prevalence of nonsusceptibility to penicillin was 28%, 
majority of which displayed intermediate resistance to penicillin (99%) and only 1% 
showing high-level resistance. Our findings are in accordance with findings by 
Song et al (128) who conducted a prospective observational study of 233 adult 
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patients with pneumococcal pneumonia in nine Asian countries. Results showed 
no statistical differences in mortality among patients with multi-drug resistance 
(14.9%) or without multi-drug resistance (15.6%) (n=233, OR 0.9, 95% CI 0.3-3.2, 
p=1.0). Additionally, a study conducted by Feikin et al (6) in San Francisco showed 
no statistically significant association between mortality and penicillin- and 
cefotaxime-resistant pneumococci. Our study shows that the recent occurrence of 
widespread antibiotic resistance has not resulted in significant increases in IPD 
mortality in this study population. We did not compare phenotypic resistance to 
concordant therapy in our study. 
 
Vaccine serotypes found in PCV-13 were not found to be associated with 
mortality. However, when restricted to meningitis patients, vaccine serotypes were 
found to be significantly associated with an increased risk of dying (OR 1.39, 95% 
CI 1.03-1.97). As previously mentioned, these vaccine serotypes may be expected 
to become less common in adults as a result of indirect effects following routine 
immunization in infants. An ecological study performed in the U.S by Tsai et al 
showed a 32.7% decrease (from 0.10 to 0.07 per 100 000) in the overall 
pneumococcal meningitis rates and a 43.9% decrease (from 0.34 to 0.19 per 100 
000) in mortality rates in individuals ≥65 years of age. In addition, for all age 
groups, a decrease in pneumococcal meningitis hospitalizations (3330 
hospitalizations were prevented) and deaths (394 deaths were prevented) after 
PCV-7 introduction compared to the baseline years (1994-1999) was seen. It 
would be interesting to see if similar changes are seen post vaccine introduction in 
South Africa (129).  
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Gender, race, prior antibiotic use within 24 hours of admission, nosocomial 
infections and vaccine serotype were not associated with mortality.  
 
4.2 Representativeness of the study population 
The study population included in the multivariable analysis were patients from 
enhanced sites who had complete case report forms with information regarding in-
hospital outcome, HIV status, admission date, prior antibiotic usage and discharge 
diagnosis. We assessed whether the population at enhanced sites differed from 
those at non-enhanced sites. There were significantly more cases reported at non-
enhanced sites compared to enhanced sites from the provinces with intermediate 
poverty rates and high poverty rates compared to low poverty rates. This could be 
attributed to enhanced sites being larger academic hospitals located in well-
resourced cities. In addition, patients belonging to White, Colored and Indian race 
groups were more likely to present at enhanced sites compared to non-enhanced 
sites. This could be due to the fact that the biggest enhanced sites in some 
provinces are in urban settings were the hospitals are larger and the population is 
more dense and diverse. This may have introduced selection bias and may limit 
the generalizability of our data to the more urban and peri-urban populations.  
 
Positive blood specimens were more likely to be collected from enhanced sites 
compared to non-enhanced sites as blood cultures are less likely to be taken at 
smaller, rural hospitals.  There were more positive CSF specimens collected at 
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non-enhanced sites compared to enhanced sites. CSF specimens are usually 
taken in a standard fashion due to the more severe clinical presentation of 
meningitis and it is assumed that clinicians will very seldom treat meningitis 
empirically without taking a CSF specimen. 
4.3 Potential study biases 
4.3.1 Collection of exposure and outcome data 
 
Systematic differences may have occurred due to differences in interviewing skills 
between surveillance officers. However, the use of strict case definitions for 
exposure and outcome may have reduced information bias.  The study population 
includes hospitalized patients nationally. Some patients may die at home without 
being admitted. This could introduce selection bias to the study. A common 
limitation with surveillance data is missing information. Data with regards to deaths 
due to IPD post admission are not available. In addition, patients who refuse to be 
admitted and treated at the hospital may die at home. This could result in 
underestimation of mortality. This study used cases from enhanced sites which 
may introduce selection bias. This may limit the generalizability of the study to 
populations beyond the enhanced sites.  
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4.4 Residual confounding 
All factors of interest were assessed in a univariate model to find out if they were 
associated with mortality. Significant factors at p≤0.1 were included in the 
multivariable logistic regression model. Each factor was then controlled for the 
confounding effect of the other. This method helped to control for the confounding 
effect of several factors at the same time. Factors significant at p≤0.05 were then 
considered significant risk factors for mortality. However, residual confounding 
effect in the association between the risk factors identified and mortality remains a 
possibility. All factors associated with IPD that could also be risk factors for death 
such as socioeconomic status and access to health services were not examined 
due to the lack of data.  
4.5 Study strengths 
Strength of this study includes the use of national data of laboratory confirmed 
cases of IPD. The large number of cases and the several years of surveillance 
data powered the study to evaluate the association between serotypes and 
mortality, controlling for other risk factors. In addition, serotyping methods 
remained consistent over the years. 
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4.6 Study limitations 
Our study has limitations. An inherent property of laboratory-based surveillance for 
pneumococcal disease is the underestimation of the actual burden of 
pneumococcal disease (130). Surveillance studies represent the proportion of 
isolates obtained only from patients from whom specimens were taken. The 
proportion of cases presenting from enhanced sites differed from non-enhanced 
possibly due to patient self-referral patterns, hospital sizes, specimen-taking 
practices and more dedicated staff at enhanced sites. This limits generalizability 
and may have introduced selection bias. Pneumococcal meningitis diagnosis was 
defined by a positive CSF culture or a positive blood culture and clinical diagnosis 
of meningitis. This could have resulted in the over diagnosing of patients with 
meningitis. 
 
 Another limitation is that the cohort used for the multivariable analysis comprised 
26% of the total cohort. This was after only including patients presenting at 
enhanced sites who were infected with the top 20 most common serotypes. The 
reduction in specimen size was also due to the failure to obtain clinical record 
reviews (17%) and non-viable isolates (22%). Possible explanations for no clinical 
review could be that patients are discharged or die before the surveillance officers 
are able to complete the case report forms. Surveillance officers sometimes find it 
challenging to complete the case report forms or obtain consent after patients 
have been transferred to other hospitals and patient files are sometimes mislaid 
79 
 
during hospital transfers. Possible reasons for non-viable isolates could be due to 
contamination or incorrect inoculation and incubation of the Dorset medium. 
 
In addition, we could not be sure that death was due to IPD. Death could have 
occurred as a result of other conditions. To minimize this we restricted our analysis 
to death that occurred within 30 days from the first positive result for S. 
pneumoniae.  
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CHAPTER 5 
5.1 Conclusion 
In conclusion, we found that amongst the 20 commonest serotypes, the incidence 
of serotypes 4, 19A, 23F and 18C increased significantly, and serotypes 1, 25 and 
5 decreased significantly from 2003 to 2008. Serotype 1 was the commonest 
serotype overall (16%), followed by serotype 19A (11%) and serotype 4 (7%). The 
CFR for meningitis was 55% and 23 for bacteremia. Serotype 19F had the highest 
CFR of 48%, followed by 39% for serotype 23F and 38% for serotype 1.  
 
Analyzing the 20 most common serotypes, using multinomial regression, 
comparing the age distribution of all other serotypes to the age distribution of 
serotype 4 (25-44 years as the referent group), serotype 3 was significantly more 
likely to be identified from patients 45-64 years of age, serotype 1 was significantly 
more likely to be isolated from patients 15-24 years of age and serotype 19F was 
significantly more likely to be isolated from patients 45-64 years of age. 
 
In comparison with serotype 4, serotypes 12F and 9V caused significantly more 
disease in HIV-infected individuals and serotype 1 was significantly less likely to 
be identified in HIV-infected patients. Serotypes 19A, 3, 6A, 14, 23F, 12F, 9N, 7F, 
18C, 25, and 5 differed when compared to serotype 4 by clinical syndrome. 
Serotypes 6A, 23F, 12F, 18C were more likely to cause meningitis, while 
serotypes 19A, 3, 14, 9N, 7F, 25 and 5 were more likely to cause bacteremia.  
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Serotypes 1, 23F and 19F were significantly more likely to cause death in patients 
compared to serotype 4. Serotype 25 was significantly less likely to cause death in 
patients compared to serotype 4. 
 
On multivariable analysis, disease caused by serotypes 1 and 19F compared to 
serotype 4 were independently associated to mortality. In addition, increasing age; 
living in provinces with intermediate or high poverty rates compared to provinces 
with low poverty rates; having meningitis compared to bacteremia; prior antibiotic 
treatment in the last two months; inappropriate antibiotic treatment and positive 
HIV status were independently associated with mortality. 
 
5.2 Recommendations 
There are no studies to date in South Africa that have looked at the association of 
serotypes with mortality amongst adults with IPD. Serotypes 1 and 19F that were 
found to be associated with increased mortality are included in the 10-and-13-
valent pneumococcal conjugate vaccine and may be expected to become less 
common in adults as a result of indirect effects following routine immunization in 
infants.  
 
HIV-infected adults experience increased mortality which may be reduced by more 
widespread availability of antiretroviral therapy which will in turn substantially 
improve the quality of life of HIV-infected individuals in terms of physical and 
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mental health and decrease the incidence of IPD and therefore mortality. 
Suggestions for future research include evaluating indirect effects of the 
pneumococcal vaccines on HIV-infected adults. Moreover, it is important that 
physicians in the public and private sectors are aware of S.pneumoniae resistance 
and the effective antibiotics to be used in their region. Awareness can be raised 
during conferences and meetings that physicians are likely to attend and during 
feedback sessions where findings of studies within GERMS –SA are 
communicated to principle investigators, stakeholders and policy makers.  
 
Data from South Africa may be helpful for policy makers in South Africa and other 
countries with similar populations who lack their own surveillance. They may assist 
with regard to decision making concerning additional targeted interventions 
including adult vaccination with PCV in order to alleviate the burden of IPD among 
adults. Furthermore, the results from this study again highlight the importance of 
continuous monitoring and surveillance before and after vaccination introduction in 
order to evaluate the impact of the new vaccines and potential changes with 
regard to serotype replacement. 
 
Input can be obtained from policy makers with regard to suggestions on how to 
adapt and improve the GERMS-SA surveillance so that it can be used for guiding 
policy. From the laboratory perspective, GERMS-SA surveillance can be improved 
by strengthening communication between the surveillance officers and laboratory 
staff, particularly from smaller laboratories. Laboratory information systems should 
be reliable as technical difficulties could adversely affect laboratory processes. 
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Clinicians should collect specimens in addition to treating patients empirically. This 
will in turn improve specimen collection. 
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